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INTRODUCTION 
This project is comprised of three main areas of investigation of 
human cytomegalovirus (HCMV). The first of these areas is the development 
of DNA probes derived from HCMV strain AD169 for the rapid detection of 
HCMV in clinical samples. Three probes were selected and tested against 
a large number of clinical samples. One probe was found to cross-
hybridize with herpes simplex virus types 1 and 2 (HSV-1, HSV-2) DNA 
controls. 
This observation led to the investigation of the cross-
hybridization, which was localized to specific restriction fragments of 
HCMV and HSV-1. Since the particular HSV-1 restriction fragment was known 
to encode the viral DNA polymerase, it appeared likely that the 
corresponding fragment of HCMV encoded the HCMV DNA polymerase. 
The viral DNA polymerases of HCMV and HSV are targets for a number 
of antiviral agents. Therefore, the third and most extensive area of 
investigation was the isolation and characterization of drug-resistant 
mutants of HCMV. Three mutants of HCMV AD169 which were resistant to 
ganciclovir (GCV) were isolated. Although the viral DNA polymerase is a 
target for GCV, this drug requires intracellular phosphorylation in order 
to become therapeutically active. 
The three mutants were characterized by high performance liquid 
chromatography (HPLC) for the study of GCV anabolism in infected cells. 
1 
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It was found that extracts of cells infected with each of the mutants 
contained much lower levels of the phosphorylated derivatives of GCV 
compared to the levels of the same derivatives in wild-type- infected 
cells. These data suggested that a virus-specific kinase activity 
responsible for GCV phosphorylation was decreased in mutant-infected 
cells. 
Three experimental approaches were devised to characterize this new 
HCMV GCV kinase function. The first approach was in vitro translation and 
expression of enzyme activity. Preston (121) reported that the HSV-1 
thymidine kinase (TK) activity could be detected from in vitro translation 
products of RNA isolated from infected cells. Since the TK of HSV-1 is 
known to phosphorylate GCV in HSV-1-infected cells, similar in vitro 
translation experiments were performed using HCMV mRNA. 
The second approach was marker transfer (33,114) of GCV resistance 
from mutant to wild-type virus. A cosmid library was made of one of the 
mutants. Marker transfer experiments were performed by transfecting human 
foreskin fibroblasts (HFF) with individually selected cosmids. The HFF 
were either co-transfected with wild-type genomic DNA or subsequently 
infected with wild-type virus. The transfected cells were cultured in the 
presence of GCV for selection of recombinant progeny. 
The third approach was to compare infected cell proteins from mutant 
and wild-type-infected cells by two-dimensional polyacrylamide gel 
electrophoresis. Comparison of mutant and wild- type proteins by this 
method revealed a protein which was present in the wild-type HCMV AD169 
but absent in uninfected and mutant-infected cells. 
LITERATURE REVIEW 
Structure and growth characteristics. Human cytomegalovirus (HCMV) 
is a member of the family Herpesvirideae. These viruses generally produce 
primary infections which become latent and may later reactivate. Other 
human viruses which are classified in this family include Epstein-Barr 
virus (EBV), herpes simplex types 1 and 2 (HSV-1, HSV-2) and varicella-
zoster (VZV). The growth characteristics of these viruses in cell culture 
differ with respect to permissive cell type, length of replication cycle 
and extracellular viral titer (38). HSV types 1 and 2 grow in a variety 
of mammalian cells with a short replication cycle resulting in release of 
the virions into the extracellular fluid. By comparison the only 
permissive cells for HCMV replication are human diploid fibroblasts. 
Replication occurs very slowly and there is little release of virus into 
the cell culture fluid. Repeated passage of HCMV isolates in culture may 
eventually result in measurable viral titer in the extracellular fluid, 
however, the titer varies with the particular strain of virus. There are 
a number of well-characterized laboratory strains (36,78,87,126) derived 
from clinical isolates after multiple cell-culture passage. These strains 
differ from their initial isolates by producing relatively high 
extracellular viral titers. The strain used in all of the experiments for 
this project was AD169 (137). 
The complete virion of HCMV is composed of a double-stranded linear 
3 
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DNA-containing core, an icosahedral capsid and an envelope (158, 174). 
Electron micrographs, however, have demonstrated the presence of many 
incomplete viral particles, which may contain less than the full 
complement of viral DNA (103, 174). In addition, there are "dense bodies", 
which appear to be composed of excess viral structural proteins surrounded 
by an envelope. The dense bodies carry HCMV-specific antigens but have 
no detectable DNA (137,159). Thus, the ratio of non-infectious particles 
to plaque-forming units (pfu) resulting from HCMV infection may be as 
great as 100: 1. 
The replication steps of HSV and HCMV also have been compared by 
electron microscopy. Both viruses enter cells by phagocytosis or fusion 
with the plasma membrane. Both rapidly traverse the cytoplasm to the 
perinuclear area, but HCMV nucleocapsids appear to acquire a fine 
fibrillar coat in the cytoplasm and are subsequently disassembled much 
more slowly than HSV nucleocapsids (141). Adsorption and penetration, 
therefore, occur equally rapidly in both HSV and HCMV infections, but 
replication of HCMV DNA proceeds at a much slower rate than that of HSV 
(38,169,142). 
Another difference between HSV and HCMV is that HSV infection 
rapidly shuts down host macromolecular synthesis while HCMV infection in 
permissive cells may stimulate the synthesis of cellular macromolecules 
(37). The physiological state of the permissive cell, however, affects 
the amount of cellular DNA synthesis as well as the amount of HCMV 
replication. Subconfluent cells are much more susceptible to HCMV 
infection than are confluent cells. It was demonstrated by DeMarchi and 
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co-workers (37), however, that stimulation of cellular DNA synthesis only 
occurred in abortively infected cells, while DNA synthesis in productively 
infected cells was eventually inhibited. The rate of inhibition of DNA 
synthesis is much slower than that which occurs in RSV-infected cells. 
Molecular characteristics of HCMV DNA. The size of the infectious 
HCMV genome is approximately 240 kilobase (kb) pairs, but there is some 
variation among strains (38,57,90). Replication of full-length genomes 
requires inoculation of permissive cell monolayers at a multiplicity of 
infection (MOI) of 0.1 or less. When the MOI is greater than 0.1, there 
is an increase in production of defective genomes of less than 240 kb in 
size (161). 
The structure of the HCMV genome is similar to that of HSV 1 and 2. 
There is a long unique sequence (UL) bounded by inverted repeats (IRL) and 
a shorter unique sequence (Us) also bounded by a different set of inverted 
repeats (IRS) (Figure 1). The presence of submolar fragments in 
restriction endonuclease digests of the viral DNA supports a model in 
which there are four possible genome arrangements. Inversion of each 
unique sequence and its repeats relative to the other produces the four 
structures, which are present in approximately equal amounts in infected 
cells (67,87,116,165). 
Restriction endonuclease cleavage patterns and nucleic acid 
hybridization techniques have been used to determine strain variation of 
HCMV (78,147,164). Strains of HCMV from the same species show 
approximately 80% or greater homology at the DNA level (78,126). A study 
of several strains of HCMV demonstrated, that in spite of loss or gain of 
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Figure 1. The structure of the genome of HCMV. The four arrange-
ments are generated by the ability of each unique sequence and its 
associated repeats to invert in relationship to the other. 
IRL long inverted repeat sequence 
IRS short inverted repeat sequence 
UL long unique sequence 
Us short unique sequence 
I~ 
a b 
a b d c 
b a d c 
b 
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restriction endonuclease sites, the order of homologous fragments is 
colinear for all of these strains (26,172). 
Digestion of the DNA of HCMV strains with several restriction 
endonucleases produces strain-specific "fingerprints" (150). Huang et 
al. (78) studied a group of women and their infants who had evidence of 
HCMV infection. The patterns of DNA restriction fragments of mother and 
offspring were identical for at least two restriction enzymes (BamHI and 
HindIII) and showed only minor changes in band migration with a third 
enzyme (EcoRI). Unrelated controls carried heterogeneous strains of HCMV 
with different restriction patterns for all three enzymes. Repeat 
isolates from some of the same patients over a period of as long as nine 
years had the same restriction pattern as the initial isolate. In spite 
of the apparent strain stability, however, there is as yet no 
classification of HCMV similar to that of HSV, which can be separated into 
two types by both antigenic and molecular criteria (87,158). 
A characteristic that HCMV does have in common with HSV is temporal 
expression of the viral genome (38,160,168,169). Three groups of virus-
specific proteins have been described based on their order of production 
in the infected cell. Immediate early proteins (IE) require no prior 
viral protein synthesis for their expression and are produced in 
lytically-infected cells after treatment with protein synthesis inhibitors 
or in abortively-infected cells (109,162,163). There is a switch from IE 
proteins to early (E) proteins within two hours post-infection in 
lytically-infected cells. Early proteins do not require viral DNA 
synthesis, and they are produced in the presence of viral DNA replication 
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inhibitors. Some E proteins are also produced in latently-infected cells 
(6,81). Late (L) proteins require viral DNA synthesis for expression and 
are, therefore, not produced in nonpermissive, abortively or latently-
infected cells (55,63,102). 
Another characteristic of HCMV replication is that the temporal 
expression of the genome is frequently controlled posttranscriptionally 
(55,146). HCMV early and late messages are both present early in 
infection, but the messages are not translated until the appropriate time. 
There are therefore, several factors which influence the outcome of 
HCMV infection; 1) the type and species of cell; 2) the physiological 
state of the cell (8,35,37); and 3) the temporal expression of the viral 
genome (38,160,163,169). Both cellular and viral regulatory proteins, 
involved in the temporal control may be responsible for the prolongation 
of the HCMV lytic cycle and for the determination of latency or 
persistence in non-lytic infections (8,169). 
Epidemiology. Evidence of HCMV infection is widespread. Detectable 
antibody titers and active virus excretion can be demonstrated in a high 
percentage of members of various socially-defined groups. From 20 to 60% 
of children in day care centers shed virus in their urine (1,84,118). Up 
to 2% of newborns are infected congenitally (69,154). Between 20 and 80% 
of the general adult population is seropositive (43,170,173), but 
seropositivity can be as high as 95% in homosexual men (28). Most HCMV 
infections are asymptomatic, but serious complications may occur in 
neonates or in immunocompromised hosts (120,131,155,156). 
Congenital infection is defined by isolation of virus from patient 
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specimens taken during the first week of life (11,156,176). The source 
of the virus appears to be predominately a reactivation of maternal 
infection, although occasionally primary maternal disease occurs during 
pregnancy. Symptoms range from persistent viruria to death. The severity 
of the symptoms is greatest with primary maternal infection, but factors 
such as gestational age at the time of infection and the immune response 
of the fetus may also contribute to the clinical outcome 
(10,119,120,154,155). 
Perinatal infection is also usually maternal in origin, but 
nosocomial sources may produce disease in some cases (39,69,148). The 
maternal infection is again generally a reactivation of latent virus and 
is passed to the infant through the genital tract or in breast milk 
(75,131). Many of these infants shed virus asymptomatically, but in some 
cases the children have neurologic sequelae even though they are initially 
asymptomatic. Slow psychomotor development and loss of hearing may become 
apparent at a later age (131,170). 
Current interest in the pathogenicity of HCMV stems from its 
association with blood transfusion (2, 85, 125), organ transplantation 
(16,17,66,105,153), and the acquired immune-deficiency syndrome (AIDS) 
(43,44,149). Cytomegalovirus infections under these conditions usually 
are caused by endogenous reactivation of latent virus, however, organ 
transplant and blood transfusion recipients may also be infected by 
reactivation of latent virus present in the exogenously-acquired tissue. 
HCMV has been recovered from peripheral blood leukocytes (41,175), 
which are probably the source of post-transfusion HCMV infection. 
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Multiply-transfused patients show a higher rate of seroconversion, which 
is further evidence of transmission of HMCV through blood products (2). 
It would appear, therefore, that donor blood can be a source for HCMV 
transmission. However, there is evidence that reactivation of latent 
virus can occur following transfusion. When viral isolates from a group 
of donors and recipients were compared by DNA restriction endonuclease 
analysis, the paired isolates appeared to be unrelated. (76). Most 
patients remain asymptomatic, but neonates and immunosuppressed patients 
are vulnerable to adverse sequelae (85). 
Organ transplant recipients are highly susceptible to HCMV infection 
(62,123). In many cases the source of the virus is probably a 
reactivation of latent host infection, but transmission of virus from the 
donor organ has been frequently documented (16, 105, 166). Chou (16) 
analyzed viral DNA from renal donor-recipient paired isolates for 
restriction enzyme fragment polymorphisms. Seropositive recipients were 
found to shed virus of donor origin in some cases, but viral strains 
different from those of the donors were also recovered. The donor strain 
was detected in isolates from seronegative recipients. 
In a series of cardiac transplant patients (123) the donors were 
demonstrated to be the source of HCMV when the recipients were 
seronegative. These recipients had primary HCMV infections from latent 
or infectious virus present in donor tissue or contaminating blood. The 
recipients who were seropositive for HCMV before transplantation, and who 
subsequently developed HCMV viremia, most likely had a reactivation of 
latent host virus. 
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Finally, HCMV infection is found in close to 100% of patients with 
AIDS (42,44,52). A significant number of these patients may experience 
severe HCMV infection in the form of retinitis, colitis or pneumonia. 
HCMV may cooperatively enhance the pathogenicity of the human 
immunodeficiency virus (HIV). Nelson et al. (110) reported that HIV and 
HCMV can co-infect brain cells in patients with AIDS. The mechanism of 
synergistic interaction, however, has not been determined. In these 
patients HCMV infection is most frequently a reactivation of latent 
infection, because the majority of the patients are seropositive for HCMV 
at the onset of AIDS (45,68). 
Latency and oncogenicity. Since reactivation of latent HCMV 
infection appears to be a significant factor in the pathogenesis of the 
virus, there have been a number of studies to determine the site of the 
latent infection. Polymorphonuclear and adherent mononuclear leukocytes 
seem to be the most likely sources of inactive virus 
(32,41,83,114,132,139). In situ hybridization experiments have 
demonstrated the presence of viral DNA and RNA in both of these cell types 
in the peripheral blood. Human lymphocytes and monocytes can be infected 
with HCMV in vitro, but this results in abortive infection (132). Factors 
which may trigger activation of the virus include infection with another 
agent (43,52), host immunosuppression (85) or host response to allogenic 
cells (17,114). 
There is evidence that HCMV may also be oncogenic (19,108). Three 
transforming regions of the genome of strains AD169 and Towne have been 
mapped to the UL (XbaI C fragment of AD169). Each of these is designated 
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as a morphological transforming region (mtr), which is capable of 
neoplastic transformation of established rodent cell lines. The mtrI is 
a non-coding region, which can transform NIH 3T3 cells. The sequence can 
form a stem-loop structure similar to an insertion element (109). Both 
mtrII and mtrIII transform rodent cell lines (47). There are open reading 
frames in mtrII in addition to potential stem-loop strutures (130). No 
transforming proteins have been identified. Transcriptional activation or 
genetic rearrangement by HCMV DNA elements may be responsible for cell 
transformation. 
In a recent study (7) it was reported, that HCMV infection activates 
the proto-oncogenes c-fos, c-jun and c-myc. Increased production of all 
three proto-oncogene mRNAs was noted as an immediate early event in HCMV 
infection. Inactivated virus was still able to cause an increase in the 
proto-oncogene mRNA levels, therefore, viral protein synthesis was not 
required. It was postulated that interaction of the virus with the cell 
surface might be the mechanism of activation, but the role of this 
activation in HCMV oncogenesis remains speculative. 
Susceptibility to Antiviral Agents. Another factor which adds to 
the seriousness of HCMV infection is the resistance of this virus to many 
antiviral agents including acyclovir (ACV). One agent which has proven 
effective in treatment of severe HCMV infection is 9-(1,3-dihydroxy-2-
propoxymethyl)guanine (DHPG). DHPG is now more commonly referred to as 
ganciclovir or GCV. 
GCV has been used experimentally to treat severe HCMV infections 
especially in transplant or AIDS patients (27,24,94). It is currently 
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approved for treatment of HCMV retinitis. Most clinical and laboratory 
strains remain sensitive to GCV (106,122), but increased resistance has 
been reported among both types of isolates (4,24,48). Neutropenia is a 
side-effect of GCV treatment, which limits the usefulness of this drug for 
some patients (94). 
A second antiviral agent which has been clinically tested for 
inhibitory activity against HCMV is phosphonoformic acid (PFA or 
foscarnet) (167). There are also adverse side-effects associated with 
this agent. Manischewitz et al. (99) demonstrated a synergistic 
inhibition of HCMV by GCV and PFA for both clinical isolates of HCMV and 
the laboratory strain AD169. Both drugs inhibit viral DNA polymerase 
activity, but the target site within the polymerase is probably different 
for each drug. In addition the toxicities of GCV and PFA differ. The 
synergy might allow treatment with lower doses of each drug, and thus, 
minimize the adverse side-effects of the individual agents. 
In addition to treatment of HCMV infections antiviral agents have 
been used in the selection and isolation of resistant mutants. Viral 
genes related to drug activity can be mapped from these mutants. The HSV-
1 DNA polymerase coding sequence was functionally determined in this 
manner (20,58,71,72,88,127). Agents whose target is the DNA polymerase 
include phosphonoformic acid (PFA) (112), phosphonoacetic acid (PAA) 
(40,74) and aphidicolin (Aph) (80,111). Several other agents which target 
the polymerase also must be activated by cellular or viral kinases. Among 
these agents are 9-~-D-arabinofuranosyladenine (Ara A) (22), 5'-iodo-2'-
fluoroaracytosine (FIAC), 5'-iodo-2'fluoroarauracil (FIAU) (25,100), ACV 
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(93,138) and GCV (15,31,50,53,143). Cellular enzymes phosphorylate AraA 
(30). FIAC, FIAU, ACV and GCV are monophosphorylated in HSV-1-infected 
cells by the viral TK. These agents are only phosphorylated at low levels 
by the cellular TK (5,25,30). Di- and tri-phosphorylation is thought to 
be carried out by cellular enzymes. This means that drug-resistant 
mutants of the virus may be separated into two classes: 1) thymidine 
kinase mutants in which the enzyme fails to phosphorylate the drug and 
2) polymerase mutants in which the altered enzyme is no longer a target 
for the drug. 
(23,93,138). 
Both types of mutants have been described for HSV-1 
Although cellular thymidine kinase activity is increased in HCMV-
infected cells, no viral thymidine kinase activity has been demonstrated 
(49,53,177). The fact that HCMV is sensitive to GCV, however, suggests 
that monophosphorylation of this drug in HCMV-infected cells requires a 
viral function. In addition there is evidence, that the cellular thymidine 
kinase activity induced by HCMV infection is completely separable from the 
"GCV kinase" activity (4,5,53). Therefore, there also may be two classes 
of HCMV GCV-resistant mutants. 
There have been only two reports of HCMV drug-resistant mutants. 
D'Aquila and Summers (34) isolated PAA-resistant mutants and Biron et 
al.(4) characterized a GCV-resistant mutant. In both cases the mutants 
were selected by growing the wild-type virus in increasing concentrations 
of the drug. Unlike HSV there have been no one-step high-level drug-
resistant mutants of HCMV reported to date. 
Rapid detection of HCMV. The potentially severe consequences of 
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HCMV infection and the availability of antiviral agents make rapid 
diagnosis desirable (133). Cell culture is usually very slow, but it is 
still the standard identification method for comparison with newer more 
rapid techniques. Two techniques which show the most promise for rapid 
viral identification are: 1) detection of viral antigens with monoclonal 
antibodies, and 2) hybridization of viral nucleic acids with labeled 
probes. 
Monoclonal antibodies specific for HCMV are available commercially. 
Detection of infected cells by immunofluorescence is now widely used in 
conjunction with cell culture (61,82,96,101,145). The sensitivity of the 
method is still not high enough to detect all HCMV-positive specimens, but 
for screening purposes it is very useful. One disadvantage of the 
immunofluorescence method is that it still requires cell culture for 
antigen amplification. 
The use of DNA probes for detection of HCMV can be applied directly 
to clinical specimens. Probes labeled with 32P are sensitive 
(11,18,140,150,151), but the isotope has a short half-life and is 
hazardous. Nonisotopically-labeled probes have been developed to avoid 
these problems (9,12,92,95,97,107), but the sensitivity has been lower 
as compared to that of the radioactive probes. 
Amplification of probe target sequences by the polymerase chain 
reaction (PCR) has improved significantly the sensitivity of hybridization 
methods (13,73,115). Selection of primers, however, is critical, since 
variation in clinical isolates may prevent primer binding and subsequent 
amplification. Hsia et al.(73) used two sets of primers homologous to 
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sequences at opposite ends of the genome. The PCR amplification produced 
positive results in all culture-positive specimens. Olive et al. (115) 
reported that the PCR method of detection in clinical samples was only 
positive when the same sample was scored as positive with at least one 
other method (culture, immunofluorescence or direct probe hybridization). 
The assay has, therefore, been reported to be as sensitive as cell culture 
and results are available rapidly. 
It is apparent that there have been recent advances in detection 
and treatment of HCMV infections. These advances are in large part the 
result of a better understanding of the molecular biology of both HSV and 
HCMV. Detection methods are based on characterization of both virus-
specific antigens and selected regions of the DNA genome. The design of 
antiviral agents requires an understanding of the function of virus-
specific proteins and the transcriptional and translational control of 
their expression. Knowledge of the genome organization and viral products 
of HSV has provided a basis for many of the experiments for HCMV. HCMV 
is a much more difficult viral system to work with than HSV, and for this 
reason the level of understanding of the mechanisms of HCMV pathogenesis 
still lags behind that of HSV. 
MATERIALS AND METHODS 
Virus. HCMV strain AD169 (134) was obtained from Dr. Marc Beem at 
the University of Chicago. Clinical isolates of HCMV, HSV-1 and HSV-2 
were collected from the Clinical Microbiology Laboratory at Loyola 
University Medical Center. Additional clinical isolates of HCMV were 
collected by Dr. Mary Christensen, Childrens Memorial Hospital, Chicago, 
IL. 
Virus stocks were frozen and maintained at - 70° C in medium 
containing 10% dimethylsulfoxide (DMSO) and 10% fetal calf serum (FCS). 
Stocks were propagated by inoculation of permissive cell monolayers at an 
MOI of 0.01-0.001. Virus stocks were harvested 3 days after the 
appearance of 100% CPE. 
Cells. Human foreskin fibroblasts (HFF) at passage 5- 7 were 
purchased from Bartels, Bellevue, WA, and maintained in Eagle's minimum 
essential medium (MEM) (Hazelton, Denver, PA or Gibco, Grand Island , NY) 
supplemented with 1% FCS (Gibco), 7.5% NaHC03 (to adjust pH to 7.2), L-
glutamine (1 mM), HEPES buffer (20 mM) (Flow Laboratories, Mcclean, VA), 
gentamicin (50 µg/ml) (M.A. Bioproducts. Walkersville, MD) and 
amphotericin B (Gibco) (2.5 µg/ml). Confluent monolayers were passaged 
1:2 and grown to confluency in Eagle's MEM containing the same supplements 
except 10% FCS. Earles balanced salt solution (EBSS) (Flow Laboratories) 
was used for washing cell monolayers. 
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Mycoplasma testing. Virus stocks of AD169 and mutant D6/3/l were 
tested for mycoplasma contamination by culture on Mycotrim RS and Mycotrim 
GU triphasic medium (Hana Biologics, Inc. Almeda, CA). In addition HFF 
monolayers inoculated with each stock were sent to Program Resources, 
Inc., McClean VA (formerly Flow Laboratories) for more extensive testing. 
This testing included Hoechst staining of infected cells, monoclonal 
antibody fluorescent staining specific for !:L.. hyorrhinis, and culture of 
both cell culture fluid and cells. 
Antiviral agents. All antiviral agents were reconstituted in 
distilled water except for aphidicolin, which was reconstituted in 10% 
DMSO. The stocks were filtered through a 0.2 µm filter for sterility. 
The following is a list of the agents and manufacturers: 
1) Adenine 9-fi-D-arabinofuranoside (AraA); thyrnine-1-D-arabino-
furanoside (AraT); aphidicolin (Aph); phosphonoacetic acid (PAA) and 
phosphonoformic acid (PFA) all from Sigma, St. Louis, MO. 
2) 5-iodo-2'-fluoroarauracil (FIAU); 5-iodo-2'-fluoroaracyto-
cytosine (FIAC) both a gift from Bristol-Myers, Wallingford, CT. 
3) Acyclovir (ACV) from Burroughs Wellcome, Research Triangle 
Park, NC. 
4) Ganciclovir (GCV) a gift from Burroughs -Wel lcome, Research 
Triangle Park, NC and Syntex, Palo Alto, CA. 
Plague assay. The method of Wentworth and French (171) was modified 
for titering and plaque purifying virus. HFF cells were grown to 80-90% 
confluency in 24-well tissue culture plates. Ten-fold viral dilutions 
were made in maintenance medium for inoculation. Growth medium from the 
20 
wells was removed and replaced with 0. 1 ml inoculum. The virus was 
allowed to adsorb for 2-4 hat 37° C. The inoculum was removed at the end 
of the adsorption period and replaced with an overlay of equal parts 0.6% 
agarose and double strength maintenance medium. Seven days later a second 
overlay of the same composition was placed on top of the first. Fourteen 
days were usually required for reading of titers and plaque purification. 
Extraction and purification of viral DNA. Virus stocks were 
propagated in either tissue culture flasks (150 cm2) or roller bottles 
(850 cm2). Each monolayer was inoculated at subconfluency at an MO! between 
0.1 and 0.01. The supernatant was harvested 3 days after 100% CPE was 
observed. 
A modification of the method of La Femina and Hayward (91) was used 
to extract the DNA. Infected cell culture fluid was centrifuged at 7,000 
rpm for 10 min in a Sorvall GSA rotor. The supernatant was centrifuged 
at 12, 000 rpm for 90 min in the same rotor. The pelleted virus was 
resuspended in a buffer containing 0.1 M NaCl, 0.01 M Tris-HCl pH 8.0, 
0.01 M EDTA. Heat-treated RNase A (20 µg/ml) was added to the virus 
suspension, which was then incubated at 37° for 60 min. Sarkosyl (2%) and 
SDS (0.5%) were added, and the lysate was incubated at 37° C for 60 min. 
Predigested Pronase (1 mg/ml) was added and incubation was continued 
overnight. After extraction with phenol:chloroform:isoamyl alcohol 
(50:48:2) the aqueous layer was precipitated with two volumes of ice-cold 
95% ethanol. The precipitated DNA was centrifuged and DNA pellets were 
redissolved in TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA). 
Cloned restriction fragments. Approximately 1 µg of HCMV strain 
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AD169 DNA was digested to completion with BarnHI. The vector pBR322 was 
linearized with BarnHI. The digests were ethanol precipitated and 
redissolved in ligase buffer (60 mM Tris-HCl pH 8.0, 33 mM NaCl, 10 mM 
MgC12) containing ATP (0. 5 mM) and DTT (5mM). The ligation reaction 
mixture contained the precipitated digests of insert (HCMV) DNA and vector 
(pBR322) DNA at a concentration ratio of 10:1 and 1 unit of T4 ligase. 
The streptomycin-resistant E_. coli strain SF8 [genotype: hsrR-, 
hsdM-, recB, recC, lop-11 (ligase overproducer) supE44), gal-96, leuB6, 
thi-1, thr; a gift from Dr. Masayasu Nomura, University of Wisconsin] was 
grown in an overnight preculture in 5 ml of Luria broth (Gibco). A 0.2 
ml sample of this preculture was added to 20 ml of Luria broth and grown 
to a Klett reading of 100. The bacteria were sedimented by centrifugation 
at 5,000 rpm in a Sorvall SS-34 rotor for 5 min at 2° C. The pelleted 
cells were resuspended in 10 ml cold 50 mM CaC12 and incubated for 60 min 
at 0° C. The centrifugation and resuspension steps were repeated in a 1 
ml volume of CaC12 . The bacteria were then added in a 2:1 (v/v) ratio to 
the ligation mixture. The transformation sample was incubated for 2 min 
at 37° C for 20 min. Dilutions of the cells from the sample were then 
plated out on Luria agar plates containing ampicillin (100 µg/ml) or 
tetracycline (10 µg/ml). Colonies which appeared on the plates were 
numbered and picked to duplicate plates containing either ampicillin or 
tetracycline. Colonies which were resistant to ampicillin but sensitive 
to tetracycline were selected for further plasmid analysis. Insert 
fragments were identified by restriction endonuclease digestion patterns 
based on the map published by Greenaway et al ( 6 7) . There are 67 
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recombinant clones which compose a partial HCMV AD169 genomic library. 
EcoRI restriction fragments of HSV-1 strain KOS DNA inserted in the 
vector pBR328 were kindly provided by Dr. Myron Levine, University of 
Michigan, Ann Arbor. In particular pSG17 and pSG87 (64) containing the 
HSV-1 EcoRI M and N fragments respectively were used as radiolabeled 
probes. 
Plasmid DNA Isolation. Large-scale plasmid isolation was performed 
by the alkaline lysis method described by Maniatis (98). A 5 ml Luria 
broth preculture containing 100 µg/ml ampicillin was inoculated with the 
recombinant bacterial strain and incubated at 37° C with shaking overnight. 
The bacteria were harvested by centrifugation at 7,000 rpm for 10 min at 
4° C in a Sorvall GSA rotor. The pellet was resuspended in 5 ml of a 
solution containing 50 rnM glucose, 25 rnM Tris-HCl pH 8.0, 10 rnM EDTA and 
transferred to a 50 ml Oak Ridge tube. An additional 5 ml of the same 
solution containing 10 mg/ml lysozyrne was added and the suspension was 
incubated at room temperature for 5 min. Then 20 ml of a freshly-made 
solution containing 0.2 N NaOH, 1% SDS was added and incubation at room 
temperature was continued for 10 min. The tube was filled with an ice-
cold solution of SM potassium acetate (pH 4.8). The tubes were vigorously 
shaken and placed on ice for 10 min. The tubes were centrifuged at 18,000 
rpm for 30 min at 4° C in a Sorvall SS34 rotor. The supernatant was 
divided into two 30 ml Corex tubes and 0.6 volumes of isopropanol was 
added. The tubes were incubated at room temperature for 15 min and 
centrifuged at 10,000 rpm for 30 min also at 20° C in the SS34 rotor. The 
pellets were resuspended in 7.4 ml TE. To purify the plasmid DNA, 1 g 
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csCl and 0.8 ml ethidium bromide (lOmg/ml) were added per ml of sample 
volume. The samples were centrifuged in a Beckman VTi 6S rotor at 60,000 
rpm or a Beckman Tl-100 rotor at 86,000 rpm for 16-20 h. Plasmid bands 
were harvested from the gradients by side puncture. The ethidium bromide 
was removed by extraction with isopropanol saturated with lOX SSC (lX SSC 
is O.lS M NaCl, O.OlS M trisodium citrate). The DNA was precipitated by 
adding an equal volume of TE to reduce the salt concentration and then 
adding two volumes of ethanol. The samples were placed at - 20° C 
overnight. DNA was pelleted by centrifugation at 10,000 rpm for 20 min 
at 4° C. Pellets were resuspended in TE. 
For rapid small-scale plasmid isolation a l.S ml culture in Luria 
broth (Gibco) with 100 µg/ml ampicillin was incubated at 37° with shaking 
overnight. Samples were centrifuged for 1 min in a microcentrifuge. The 
pellets were resuspended in 100 µl of an ice-cold solution containing SO 
rnM glucose, 10 rnM EDTA, 2S rnM Tris-HCl pH 8.0, and 4 mg/ml lysozyme. The 
suspensions were incubated for S min at room temperature, and then 200 µl 
of fresh solution containing 0.2 N NaOH, 1% SDS was added followed by 
another incubation for S min at room temperature. A lSO µl volume of 
ice-cold SM potassium acetate solution pH 4.8 was added, and the samples 
were placed on ice for S min then centrifuged for S min at 4° C in a 
microcentrifuge. The supernatant was removed to a fresh tube and an equal 
volume of phenol: chloroform: isoamyl alcohol (SO: 48: 2) was added. The 
samples were centrifuged for S min at 4° C. The aqueous layer was removed 
to a fresh tube. The DNA was precipitated with 2 volumes 9S% ethanol at 
room temperature and pelleted by microcentrifugation. The pellets were 
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washed with 70% ethanol and re-centrifuged. The pellets were dried and 
resuspended in 30 µl TE (lOmM Tris-HCl pH 7.5, 1 mM EDTA) containing 20 
µg/ml RNase A. 
Agarose gel electrophoresis. Both undigested and restricted DNA 
samples were routinely analyzed by electrophoresis on horizontal 0. 7% 
agarose gels in buffer containing 89 mM Tris base and boric acid, and 2 
mM disodium EDTA (final pH 8.0). After electrophoresis, the gels were 
stained with 0.5 µg of ethidium bromide per ml of staining solution. 
Removal of insert DNA from recombinant plasmids. Recombinant 
plasmid DNA was digested with the appropriate restriction endonuclease. 
Insert DNA was separated from vector DNA by agarose gel electrophoresis, 
electroeluted from the gel and purified by passage over a DEAE-Sephacel 
(Pharmacia, Piscataway, NJ) column (98). The DNA was eluted from the 
column with buffer containing 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.6 M 
NaCl, and concentrated by ethanol precipitation. 
Alternatively restriction fragments were removed from low melting 
point (LMP) agarose (FMC BioProducts, Rockland, ME) by the method of 
Gafner et al. (54). Briefly, the agarose containing the fragment was 
heated at 65° C, extracted twice with phenol equilibrated with 50 mM Tris-
HCl pH 8.0 and once with chloroform. The DNA was concentrated by ethanol 
precipitation. 
Processing of clinical specimens for probe detection of HCMV DNA 
(18,152). Clinical urine specimens were kindly collected by Dr. Mary 
Christensen at Children's Memorial Hospital, Chicago, IL. The volumes 
ranged from 1 to 3 ml. The total volume was brought up to 8 ml with EBSS 
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without indicator. The samples were centrifuged at 2,000 x g for 5 min. 
In some samples, a portion of this low-speed-centrifugation pellet was 
examined for cells, crystals, and bacteria. The pellet was then returned 
to the supernatant, and the total sample was centrifuged at 25,000 x g for 
90 min. Alternatively the supernatant from the low-speed centrifugation 
was transferred to a new tube and centrifuged at 25,000 x g for 90 min. 
A 20-µl volume of a solution containing 0.1 M NaCl, 10 mM Tris-HCl 
pH 8.0, 10 mM EDTA, 500 µg of pronase per ml, and 0.5% SDS was added to 
the pellets from the high-speed centrifugation, and this mixture was 
incubated at 3 7° C for 1 h. The samples were transferred to 1. 5 ml 
microcentrifuge tubes, extracted twice with an equal volume of phenol-
chloroform-isoamyl alcohol (50: 48: 2), extracted once with chloroform-
isoamyl alcohol (24:1), and precipitated with ethanol. The precipitates 
were suspended in 20 µl of TE. An equal volume (20 µl) of 0.3 M NaCl/1.0 
M NaOH was added; the samples were vortexed briefly and allowed to stand 
for 15 min at room temperature. Another volume (40 µl) of 0.8 M Tris-HCl 
pH 6.8/lM NaCl was added. The entire sample was placed in a well of a 
Minifold filtration apparatus (Schleicher & Schuell, Keene, NH) for 
blotting onto a nitrocellulose filter (BA85, Schleicher & Schuell). A 
slight vacuum was applied after the wells appeared to be empty. The 
nitrocellulose filter was baked under vacuum at 80° C before further 
processing. 
Samples of HCMV, HSV-1, and HSV-2 were processed in the same manner 
as were the clinical samples. DNA from each of these viruses was 
suspended directly in 20 µl of TE and prepared for dot blotting onto 
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nitrocellulose filters as described above. 
Processing of infected cell monolayers for probe detection of HCMV 
RNA (151,152). Cell culture fluid was removed and the monolayers were 
washed with 2 ml EBSS. Monolayers were detached after washing by adding 
250 µl of a filtered 0.25% trypsin solution and incubation at 37° C for 
5 min. One milliliter of EBSS without indicator was added to each tube. 
The samples were transferred to 1.5 ml microfuge tubes and centrifuged at 
5,000 x g for 5 min. The supernatant fluid was discarded. 
The cell pellets were treated with 200 µl of lysis solution (100 mM 
NaCl, 10 mM Tris-HCl pH 8.0, 10 mM EDTA, 500 µg/ml pronase and 0.5% SDS) 
and incubated at 37° C for 1 h. The lysate was extracted twice with 
phenol:chloroform:isoamyl alcohol, once with chloroform:isoamyl alcohol 
(24:1) and ethanol precipitated. The pellets were redissolved in 20 µl 
TE. An equal volume of 1 M NaOH-2 M NaCl was added, and the suspensions 
were incubated at room temperature for 15 min. The samples were 
neutralized with 40 µl of 3 M sodium acetate pH 5.5. Each sample was 
suctioned onto either a GeneScreen Plus membrane (DuPont NEN, Boston, MA) 
or a nitrocellulose filter using a Minifold filtration apparatus as 
described above. 
Labeling of DNA probes. Two methods were used to label DNA probes. 
DNA for biotinylated probes was labeled with biotinylated dUTP by nick 
translation with reagents purchased in a kit manufactured by BRL. The 
labeled probes were separated from unincorporated nucleotides by ethanol 
precipitation. Some radioactive probes were also labeled with 32P-dCTP by 
nick translation using the same BRL kit, but unincorporated nucleotides 
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were removed by Sephadex G-50 chromatography. The Sephadex G-50 
(Pharmacia) was equilibrated in buffer containing 50 mM Tris-HCl, 10 mM 
EDTA. The nick translation mixture was loaded onto the column and the 
same buffer was used to elute the probe. Separation of probe and 
unincorporated nucleotide peaks was monitored with a Geiger counter. 
Approximately 1.5 ml of buffer containing the separated probe was 
collected directly after the predetermined void volume. 
More recently, smaller quantities of DNA (25 ng) were labeled by 
random priming with a kit purchase from Amersham, Arlington Heights, IL. 
The unincorporated nucleotides were separated from the labeled probes by 
spin columns purchased from 5 Prime-->3 Prime, Inc., West Chester, PA. 
Southern hybridizations. Agarose gels were prepared for Southern 
blotting by depurination in 0.4 M HCl, denaturation in 0.5 M NaOH-1.0 M 
NaCl and neutralization in 0.5 M Tris-HCl-1.5 M NaCl. The gels were 
blotted onto GeneScreen Plus or Nytran (Schleicher and Schuell) with lOX 
SSPE (lX SSPE is 0.18 M NaCl, 10 mM NaH2P04 , 1 mM EDTA). The membranes 
were prehybridized in 50% formamide, 0.9% SDS, 5X SSPE, lOX Denhardt's 
(lX Denhardt's is 0.02% Ficoll, polyvinylpyrrolidone and BSA) and 50 µg/ml 
salmon sperm DNA for 1-2 h at 42° C. The prehybridization solution was 
replaced with hybridization solution containing 6X SSPE, 1% SDS, 50% 
formamide, and 50 µg/ml salmon sperm DNA and heat-denatured probe. The 
membranes were hybridized overnight at 42°. 
Gene Screen Plus 
manufacturer's protocol: 
membranes were washed according to the 
twice with 100 ml 2X SSC at room temperature 
for 5 min each; twice with 200 ml 2X SSC/1% SDS at 65° for 30 min each; 
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twice with 100 ml O.lX SSC at room temperature for 30 min each. Nytran 
membranes were washed as follow: once in lX SSPE for 5 min at room 
temperature; twice in lX SSPE/1% SDS at 65° C for 15 min each; twice in 
O.lX SSPE at room temperature for 15 min each. Membranes were briefly 
air-dried and placed in X-ray cassettes with Cronex Lightning Plus 
intensifying screens (DuPont, Wilmington, DL) and Kodak X-OMAT AR film. 
The cassettes were held at -70° C for whatever period of time was required 
for the individual experiment. 
Dot-blot hybridization. Dot-blotted nitrocellulose filters were 
prehybridized in a solution containing 45% formamide, 5X SSC, 0.2% BSA, 
0.2% ficoll 400, 25 mM sodium phosphate buffer pH 6.5 and 300 µg/ml heat-
denatured calf thymus DNA. The filters were prehybridized in a heat-seal 
bag at 42° C for 2 h with shaking. 
The filters were hybridized in a solution containing the same 
components as the prehybridization plus 0.1% sodium pyrophosphate, 10% 
dextran sulfate (Pharmacia), and heat-denatured biotinylated probe. The 
filters were incubated in heat-seal bags at 42° C for 1-20 h depending on 
the experiment. 
After hybridization, nitrocellulose membranes were washed according 
to the manufacturer's (BRL) protocol: twice in 2X SSC/0.1% SDS at room 
temperature for 3 min each; twice in 0.2X SSC/0.1% SDS at 50° C for 15 min 
each; once in 2X SSC/0.1% SDS at room temperature for 3 min. 
Detection of hybridized biotinylated probe. Membranes were 
rehydrated for 1 min in BRL Buffer I (100 mM Tris-HCl pH 7.5, 100 mM NaCl, 
2 mM MgC12 , 0.05% Triton X-100). The membranes were blocked for 20-75 min 
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in freshly prepared Buffer II (Buffer I containing 3% BSA). After 
blocking, membranes were baked in a vacuum oven at 80° C for 20 min. 
Membranes were rehydrated in Buffer II for 10 min and drained. A 
solution containing 2 µg/ml Streptavidin in Buffer I was constantly 
pipetted over the membranes for 10 min at room temperature. This was 
followed by three washings in Buffer I at room temperature for 3 min each. 
A solution containing 1 µg/ml poly-alkaline phosphatase (poly-AP) in 
Buffer I was pipetted over the membranes for 10 min at room temperature. 
The membranes were then washed twice in Buffer I at room temperature for 
2 min each and twice in Buffer III (100 mM Tris-HCl pH 9.5, 100 mM NaCl, 
50 mM MgC12) at room temperature for 2 min each. A dye solution (7.5 ml 
Buffer III, 33 µl nitroblue tetrazolium (NBT), 25 µl 5-bromo-4-chloro-3-
indolyl phosphate (BCIP)] was added to the blocked membranes in a heat-
seal bag. This step was performed in very low light, and the heat-seal 
bag was placed in the dark for color development. After 2 -4 h the 
reaction was stopped by washing the membranes in a solution containing 5 
mM EDTA, 20 mM Tris-HCl pH 7.5 at room temperature for 15 min. 
Standard strips spotted with low concentrations of biotinylated DNA 
were baked for 2 h at 80° C in a vacuum oven. 
developed along with all test membranes. 
A standard strip was 
Drug resistance measured by per cent survival. Plaque-purified 
isolates of each mutant were titered in the presence and absence of a 
single high concentration of each drug. The percent survival was 
calculated from the ratio of the titer of each mutant in the presence of 
the drug to the titer of the mutant in the absence of the same drug 
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multiplied by 100. The percent survival of the wild-type was determined 
as a control for each experiment. 
Drug-resistance measured by plague reduction. The concentration of 
each drug which could reduce the number of plaques of a single viral 
dilution by fifty percent was determined. All monolayers in a 24-well 
plate were inoculated with a single viral dilution calculated to produce 
30-50 plaques per control well. The four control wells were overlaid with 
medium without drug, and the remaining wells were overlaid in 
quadruplicate with medium containing a range of drug concentration. The 
assays were read at 14 days post-infection. 
Drug-resistance measured by enzyme-linked immunosorbent assay 
(ELISA) (3,128). Monolayers in 96-well microtiter plates were inoculated 
with wild-type or mutant strains of HCMV at a single dilution. Control 
wells were inoculated with maintenance medium. The inoculum was replaced 
with medium containing two-fold dilutions of the drug. In one set of 
wells which had been inoculated with virus, the medium without drug was 
added to serve as a virus control. The plates were incubated usually for 
5-7 days until the virus control demonstrated 50% CPE (2+). 
In order to detect the amount of HCMV replication, the cell culture 
medium was aspirated and replaced with 0.2 ml phosphate buffered saline 
(PBS contains per liter: 7.65 g NaCl, 1.2688 g disodium phosphate, 0.1 g 
monosodium phosphate, 0.2133 g monopotassiumphosphate) containing 1% BSA. 
The plates were incubated at room temperature for 30 min. The PBS-BSA was 
aspirated and replaced with 0.2 ml per well ethanol:acetone 95:5, and the 
plates were placed at - 20° C for 30 min. The e thano 1 : ace tone was 
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aspirated, and the wells were washed 5 times with PBT buffer (0.05% Tween 
20 and 1% BSA in PBS). The washes were performed with an Immuno Wash 8 
(Nunc, Kamstrup, Denmark). Monoclonal antibody (Late Nuclear Protein, 
DuPont NEN) specific for an HCMV late antigen (142) was added to a 
dilution of 1:5,000 in a solution containing 10% goat serum, 1% FCS, 0.05% 
Tween 20 in a volume of 0.1 ml per well. The plates were incubated at 37° 
c for 1 h. The wells were again washed 5 times with PTB buffer, and 0.1 
ml of goat anti-mouse lg conjugated with horse radish peroxidase (Bio-Rad, 
Richmond, CA) at a dilution of 1:2,000 in a solution containing 10% goat 
serum and 0. 05% Tween 20 was added to each well. The plates were 
incubated at 37° C for 2 h followed by 5 washes in PTB. A volume of 0.2 
ml of substrate solution [2,2'-azinobis(3-ethylbenzthiazoline) sulfonic 
acid (Sigma) and 0.005% H202 ] at a concentration of 1 mg/ml was added to 
each well. Color was allowed to develop for 15-30 min. The plates were 
read on a Dynatech MR580 Microelisa Auto Reader at 405 nm. 
HPLC analysis of GCV anabolism in virus-infected cells. HFF 
monolayers in 150 cm2 flasks were inoculated with HCMV AD169 or one of 
the three GCV-resistant mutants (Dl/3/4, Dl0/3/2, D6/3/l) at an MOI of 
approximately 1.0. One flask was mock-infected for a cell control. At 
either 72 or 96 h post-infection 3H-GCV (a gift from Syntex, Palo Alto, 
CA) was added to each flask. The concentration of labeled drug was 
approximately 1 uM and cold drug was added such that the final GCV 
concentration was 50 µMand each flask contained approximately 1.67 x 107 
cpm. 
After 24 h incubation the cells were prepared for perchloric acid 
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extraction. The radioactive medium was removed from the HFF monolayers 
and replaced with 1.5 ml 0.25% trypsin per flask to detach the monolayers. 
An equal amount of growth medium was added to each flask, and the cells 
were dispersed with a pipette. These cells were placed in a 15 ml conical 
centrifuge tube. The flasks were washed with an additional 1.5 ml growth 
medium, which was then added to the 15 ml tubes. The tubes were 
centrifuged at 2,000 rpm in a Beckman TJ-6 tabletop centrifuge for 10 min. 
All but 0. 5 ml of the supernatant was removed, and the cells were 
resuspended in the remaining fluid. The cells were transferred to a 
microfuge tube, washed with 1.5 ml Dulbecco's PBS (DPBS per liter: 0.2 g 
KCl, 0.2 g KH2P04 , 8 g NaCl, 2.16 g Na2HP04 7H20). The cells were washed in 
1. 0 ml DPBS two more times. After the final wash the cells were 
resuspended in 200 µl DPBS, and 65 µl 2 M perchloric acid was added to 
produce a final concentration of approximately 0.5% perchloric acid. The 
cell extracts were vortexed and then centrifuged for 20-25 min at 4° C. The 
supernatant was transferred to a new microfuge tube and either placed on 
ice for immediate analysis by HPLC or stored at -70° C. 
GCV and GCV-monophosphate at a concentration of 100 rnM were used as 
standards for HPLC analysis of products of infected-cell GCV anabolism. 
These standards were injected in 10 µl volumes for analysis on a Partisil 
10 ODS3 250 x 4.6 mm reversed phase HPLC column (Phenomenex, Rancho Palos 
Verdes, CA). The mobile phase was 0.02 M KH2P04 pH 3.65. The perchloric 
acid extracts of infected cells labeled with 3H-GCV were assayed under the 
same conditions, but fractions were collected in scintillation vials at 
0.3 min intervals for 15 min. Scintillation fluid (10 ml Universal, ICN 
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Biomedicals, Irvine, CA) was added to each vial, and each vial was counted 
for 2 min on an LKB 1214 Rackbeta liquid scintillation counter. 
Messenger RNA isolation from virus-infected cells. Monolayers of 
HFF in 150 cm2 flasks were inoculated at an MOI of 1.0 with wild-type 
AD169 or mutant strains of virus. Messenger RNA was isolated at 72 h 
post-infection according to a kit protocol (Fast Track mRNA Isolation Kit, 
Invitrogen, San Diego, CA). Briefly, the cells were washed with DPBS and 
lysed in Stock Buffer containing 0.2M NaCl, 0.01 M Tris-HCl pH 7.5, 1.5 
M MgC12 , 2% SDS plus 0.02 volumes RNase Protein Degrader (patented by 
Invitrogen). The lysates were passed 5-6 times through a 21 gauge needle 
to shear the cell DNA and then digested for 1-2 h at 45° C to remove 
protein. The salt concentration of the lysate was adjusted to 0. 5 M 
before incubation with oligo dT for 40-60 min at room temperature. The 
oligo dT was washed repeatedly with a Binding Buffer [0.1 M EDTA, 0.01 M 
Tris-HCl (diethylpyrocarbonate-treated)] and then added to a disposable 
column. Washing was continued until the OD260 was less than 0.05. The 
poly A+ RNA was eluted with kit-supplied Elution Buffer (0.5 M NaCl, 0.01 
M Tris-HCl) into four fractions of 0.4 ml each. These fractions were 
pooled, mixed and realiquoted into four microfuge tubes to ensure that the 
mRNA concentration was the same in each tube. The RNA was precipitated 
at -20° C by adding 0.1 volume 2 M sodium acetate and 2 volumes of 100% 
EtOH. The samples were centrifuged for 30 min at 4° C, dried and 
redissolved in 50 µl TE. 
concentration of RNA. 
The OD260 was taken to determine the 
In vitro translation of mRNA from virus-infected cells. Messenger 
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RNA isolated at 72 h post-infection from virus-infected or mock-infected 
cells was used as a template for in vitro translation. A micrococcal 
nuclease-treated rabbit reticulocyte lysate (Promega) was used for the 
translation. The reaction mixture consisted of 35 µl of the lysate, 1 mM 
amino acids minus methionine, 40 units of RNasin (Promega), 50 µCi 35s-
methionine (DuPont NEN) and 5-10 µg of mRNA for a final volume of 50 µl. 
The translation mixture was incubated at 30° C for 90 min. At the end of 
the 90 min incubation the translation mix was either analyzed directly or 
stored at -70° C. 
In order to assay for GCV kinase activity associated with the 
translated proteins, the translation mixture was added to a solution 
containing 100 mM MES (Sigma) pH 6.1 (or in some experiments 100 mM Tris-
HCl pH 7.5), 2 mM magnesium acetate, 10 mM ATP, 1 unit creatine 
phosphokinase (Sigma), 6 mM creatine phosphate (Sigma), 1% BSA, and 7.5 
µCi 3H-GCV. This reaction was incubated at 30° C for 5-11 h. At the end 
of the incubation period the reaction was extracted with 0.5 M perchloric 
acid and centrifuged for 30 min at 4° C. The supernatant was transferred 
to a new tube and recentrifuged for 15 min. The supernatant was again 
transferred to a new tube and stored at - 70° C for HPLC analysis as 
described above. 
Cosmid cloning of mutant D6/3/l. Virion DNA isolated from mutant 
D6/3/l was partially digested with BamHI by serial dilution of the enzyme. 
The two concentrations of enzyme which produced fragments between 30 and 
50 kb in size were selected for the actual cloning steps. One microgram 
of D6/3/l DNA was partially digested with either 4.2 or 2.1 units of 
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enzyme. The products were checked for size on 0.3% agarose gels. Cosmid 
pWE15 (Stratagene) was linearized with BamHI and dephosphorylated with 
calf intestinal alkaline phosphatase (Boehringer-Mannheim, Indianapolis, 
IN). The cosmid and partially digested DNA fragments were ligated 
overnight at 4° C. The components of the ligation were: 1.5 µl partially 
digested HCMV DNA (lµg/µl); lµl linearized pWE (lµg/µl); 2 µl lOX ligation 
buffer (0.5 M Tris-HCl pH 7.5, 50 mM MgC12 , 50 mM DTT); 2 µl ATP 10 M 
The ligation products were packaged into phage with a 
packaging kit (Gigapack Gold, Stratagene). Briefly 4 µl of ligated DNA 
was added to a freeze/thaw extract (kit supplied). Fifteen microliters 
of a sonic extract (also kit supplied) was then added. This reaction 
mixture was incubated at room temperature for 2 h. The packaged phage 
were then treated with 20 µl chloroform. 
A culture of~ coli strain NM554 [genotype F-, recA, araD139, (ara 
leu)7696 lacY74, galU-, galK-, hsr-, strA, mcrA(-), mcrB(-)] (supplied by 
Stratagene) was grown overnight in Luria broth containing 0.2% maltose and 
10 mM MgS04 at 30° C. The bacteria were pelleted for 10 min at 4,000 rpm 
in a Sorvall SS34 rotor at 4° C. The bacteria were resuspended in 10 mM 
MgS04 to an OD600 of 0.5. Equal volumes of NM554 cells and packaged phage 
solution were incubated at room temperature for 45 min. In order to allow 
expression of beta lactamase, Luria broth (200 µl) was added to each tube 
and the tubes were incubated at 37° C for 60 min. During the incubation 
the tubes were gently shaken every 15 min. The suspension was pelleted 
for 1 min at 14,000 rpm in a Beckman microcentrifuge. The supernatant was 
removed, and the bacteria were resuspended in 50 µl of fresh Luria broth. 
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The cultures were then plated on Luria agar plates containing 100 µ.g 
ampicillin per ml and incubated at 37° C overnight. Arnpicillin-resistant 
colonies were picked to new ampicillin plates. Each recombinant was 
analyzed for cosmid content by the alkaline lysis procedure (98). Cosmids 
containing overlapping regions of the mutant D6/3/l genome were isolated 
by the large-scale alkaline lysis method (98) followed by CsCl 
purification. 
Transfection of HFF with cosmid DNA. Slightly subconfluent 
monolayers of HFF in 6-well tissue culture plates were washed with serum-
free Opti-MEM (Gibco). Cosmid DNA was diluted in Opti-MEM (6.7 µ.g/0.5 
ml). Lipofectin reagent (BRL) (14) was diluted separately in Opti-MEM (17 
µ.g/0.5 ml). Equal portions of cosmid and lipofectin solutions were added 
to a new tube and 1 ml of the combined reagents was added dropwise to the 
HFF monolayers. The cells were incubated with the transfection medium for 
24 h. The transfection medium was then removed, and the cells were 
infected with HCMV AD169 at an MOI of 1.0. The virus was adsorbed for 2 
h, at which time the inoculum was removed and replaced with 3 ml of 
maintenance medium. After 24 h incubation the medium was removed and 
replaced with maintenance medium containing 100 µ.M GCV. Incubation was 
continued for 3-7 days. Infected monolayers were then scraped from the 
plates and passed to uninfected monolayers for further selection in the 
presence of 100 µ.M GCV. 
Alternatively the monolayers were infected with AD169 2 h before 
transfection with cosmid DNA. At the end of the transfection period 
maintenance medium containing 100 µ.M GCV was added directly. In some 
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experiments monolayers were co-transfected with cosmid and AD169 DNA 
instead of infection with intact virus. Selection with GCV was delayed 
for 24-48 h post-transfection. 
Control monolayers were transfected with cosmid vector pWElS DNA. 
The plasmid carries the gene for neomycin resistance for selection. The 
neomycin analogue G418 (400 µg/ml) was added at 48-72 h post-transfection. 
In addition there were control monolayers which were mock-transfected to 
determine cell viability after Lipofectin exposure. 
Two-dimensional gel electrophoresis. Translation products from in 
vitro translation of infected cell mRNA were analyzed by two-dimensional 
polyacrylamide gel electrophoresis (113). The first dimension was an 
isoelectrofocusing (IEF) gel. Tube gels consisting of 8. 8 M urea, 4% 
acrylamide, O.S% bisacrylamide, 2% NP-40, 4% ampholine pH S-7 (Pharmacia 
LKB), 1% ampholine pH 3-10 (LKB), 0.01% ammonium persulfate and 0.067% 
TEMED (Bio-Rad) were cast in a 20-gel apparatus (Electro-Nucleonics, 
Siversprings, MD) and allowed to polymerize for 2 h. The gels were pre-
run for 1 h at 200 V. The anode buffer was 10 mM phosphoric acid and the 
cathode buffer was 20 mM NaOH. A 20 µl volume of the translation reaction 
mixture was added to SO µl of sample buffer containing SO mM CHES, 2% SDS, 
1% DTT, 10% glycerol. The samples were run for 16-17 h at 800 V. The 
gels were then extruded into equilibration buffer containing 0.12S M Tris-
HCl pH 6.8, 2% SDS, 8.6 mM dithiothreitol, 10% glycerol and a trace of 
bromphenol blue. 
The first dimension gels were placed at the top of SDS 
polyacrylamide slab gels (10% acrylamide, 0.9% bisacrylamide, 0.3% SDS, 
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0.05% ammonium persulfate and 10 µl TEMED per 30 ml volume). The second 
dimension gels (SDS-PAGE) were electrophoresed for 2.5-3 h at 30 mA per 
gel in a buffer containing 25 mM Tris-HCl pH 8.3, 192 mM glycine. The 
gels were fixed in 30% methanol, 10% acetic acid for 1 hand then enhanced 
in 5 volumes of Enlightning (DuPont NEN) for 30 min. The gels were dried 
with heat and vacuum and placed in X-ray cassettes with Kodak XO-MAT AR 
film for 48-90 h. The films were developed for 4 min in GBX Developer 
(Kodak). Development was stopped by rinsing the films in tap water. The 
films were fixed for 2 min in GBX Fixer (Kodak). 
Proteins extracted from infected cells were also analyzed by 2-D 
gel electrophoresis. HFF monolayers in 150 cm2 flasks were infected with 
stocks of mutant or wild-type strains at an MOI of 1.0-2.0. Monolayers 
were incubated for 48 h in normal maintenance medium. The medium was then 
replaced with methionine-free medium (Gibco) containing 1% FCS, gentamicin 
(50 µg/ml), amphotericin B (2.5 µg/ml) and 35s-methionine (25 µCi/ml, 
specific activity 1,000 Ci/rnmol) plus 10% normal maintenance medium. 
After 24 h the cells were harvested as follows: the monolayers were 
washed with lX DPBS; the cells were scraped into 4 ml PBS, dispersed by 
pipetting and centrifuged at 1,000 x g for 10 min. Cells were resuspended 
in lX DPBS and centrifuged again. This step was repeated two more times. 
After the final pelleting, cells were resuspended in 2 ml DPBS and 
transferred to 4 microfuge tubes. The cells were pelleted in a 
microcentrifuge for 10 min. The supernate was removed, and the cells were 
solubilized in 20-30 µl of urea solubilizer [9 M urea, 4% NP-40, 2% 
ampholyte (9-11 range), 2% mercaptoethanol] for 2 h with frequent 
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vortexing. Solubilized proteins were stored at -70° C until analyzed by 
2-dirnensional gel electrophoresis. The 2-dirnensional gel analysis was 
performed by Lori Berg in the laboratory of Dr. Chung Lee at Northwestern 
University Medical Center, Chicago, IL. 
RESULTS 
Selection of HCMV probes. In order to develop DNA probes for the 
rapid detection of HCMV in clinical specimens, regions of the HCMV AD169 
genome were selected. The feasibility of this method was based on the 
fact that there is at least 80% homology among the genomes of HCMV strains 
which have been tested (26). The greatest variability has been reported 
around the junction of the unique and repeat segments (90, 147). The 
unique segments are colinear even though restriction endonuclease sites 
may be altered (26). Large restriction fragments from unique regions of 
the genome of HCMV AD169, therefore, would contain sufficient homology 
with comparable regions of the genomes of clinical strains of HCMV to 
allow hybridization under moderately stringent conditions. 
The HCMV AD169 BarnHI B fragment inserted in pBR322 was selected 
initially as a probe because of its size (15 kb) and position in the 
genome (UL sequence; Figure 2). The intact recombinant plasmid carrying 
this fragment was used as the probe in all experiments. 
The BarnHI D (13 kb, UL) and H (10 kb, U5 ) fragments cloned in pBR322 
were also selected as probes because of size and position in the genome. 
The vector sequences were removed from the fragments before they were used 
as probes. 
In order to determine the minimum amount of homologous HCMV AD169 
DNA which each probe could detect, each of the three probes was hybridized 
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Figure 2. Restriction enzyme map of the HCMV AD169 genome. From 
Greenaway et al . ( 6 7) . 
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All of the probes 
detected a minimum of 30 pg of homologous HCMV DNA (Figure 3). 
Detection of HCMV DNA in clinical specimens. A total of 61 urine 
specimens submitted for culture to the Virology Laboratory at Children's 
Memorial Hospital were processed for direct detection of HCMV with the 
biotinylated BamHI B fragment as a probe. Samples of 1 to 3 ml from each 
specimen were prepared for dot-blotting on nitrocellulose filters as 
described in Materials and Methods. Similarly processed samples 
containing DNA extracted from laboratory strains of HCMV, HSV-1 and HSV-
2 were included as controls. 
The comparison of culture and hybridization results for the B 
fragment are shown in Table 1. Additional information concerning the 
length of time required to produce visible CPE and the amount of CPE 
present in the culture-positive specimens was collected after the 
hybridization reactions had been recorded. There were 15 specimens which 
were scored positive by both methods, whereas 14 specimens were scored 
positive by culture but negative with the probe. Four specimens were 
weakly positive with the probe but remained culture negative. The 
sensitivity of the probe detection method was 52%, and the specificity 
was 87.5%. There was 70.5% agreement between the results of hybridization 
and culture methods. The amount of CPE in cell culture, however, did not 
correlate with the probe results. In several samples the reported CPE was 
l+ to 2+, and the probe did not detect the presence of virus. Conversely, 
there were specimens which produced a strong color reaction with the probe 
but which yielded only a few lesions in the cell culture tubes. 
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Figure 3. Hybridization of selected probes with dot-blotted HCMV AD169 
DNA. Dilutions of CsCl-purified total genomic HCMV AD169 DNA were 
hybridized with each single-probe BamHI fragment (B,D, and H), as 
well as with the combined D and H probes. Amounts of HCMV DNA are 
shown at the top of each column. Control solutions containing no 
DNA are in column C. Hybridization was performed for 18 h, and 
color development for detection of hybridized probe was allowed for 
the maximal 4 h recommended by the manufacturer (BRL). 
Probe 
1 DO 1 0 1 1 00 31 1 C 
ng ng ng pg pg pg 
B 
• 
D 
H 
D and H 
• 
TABLE 1. Comparison of results for detection of HCMV in clinical specimens 
by cell culture and DNA probe hybridization. 
DNA probe Cell culture 
results Positive Negative Sensitivity Specificity Agreement 
(%) (%) (%) 
BamHI B 
Positive 15 4 52 87.5 70.5 
Negative 14 28 
BamHI D+H 
Positive 17 5 81 68.8 75.7 
Negative 4 11 
BamHI H 
Positive 11 5 78.6 76.2 77 .1 
Negative 3 16 
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Detection of HCMV with combined BamHI D and H fragment probes. 
During the course of these experiments it was reported that a portion of 
the HCMV EcoRI restriction fragment I contains sequences which weakly 
hybridize with mammalian cellular DNA (135). The region of the EcoRI 
fragment which is homologous with the cellular DNA is also contained 
within the BamHI B fragment. In order to avoid the possibility of cross-
hybridization, the HCMV BamHI D and H restriction fragments (Figure 2) 
were used instead of the B fragment in subsequent experiments. Each of 
these fragments is in a region of the genome which has no reported 
homology with mammalian DNA. Two changes were made in the detection 
procedure in these experiments, both aimed at increasing the sensitivity 
of the detection method. The first change was the use of two fragments 
(BamHI D and H) as combined probes (151). The second change was the 
elimination of the initial low-speed centrifugation of the urine samples 
to prevent the loss of any cell-associated virus present in the specimens. 
A total of 37 specimens submitted for culture were processed for 
direct detection with the combined biotinylated D and H probes (Table 1). 
There were 17 specimens which were positive by both methods, 4 specimens 
which were probe negative and culture positive, and 5 specimens which were 
weakly positive with the probe but which remained culture negative. The 
sensitivity of the combined probes was 81.0%, and the specificity was 
68.8%. The agreement between probe and culture results was 75.7%. The 
amount of CPE again did not correlate with the color intensity of the 
probe hybridization. Of the five probe-positive, culture-negative 
specimens, one was from a patient who had had previous positive cultures. 
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Probe hybridization with HSV virion DNA. There was significant 
hybridization of the new probes with HSV controls prepared along with the 
clinical samples (Figure 4). To determine how the observed hybridization 
with HSV was related to the use of the new probes, duplicate filters were 
prepared with dot blots of HSV-1, HSV-2, and HCMV virion DNA prepared in 
the same manner as the clinical specimens. Each filter was hybridized 
with one of the fragments. Comparison of these two filters shows that the 
D fragment hybridized to each of the HSV samples, whereas the H fragment 
produced a positive signal only with HCMV DNA (Figure 5). 
Analysis of cross-reactivity with HSV-1. Southern blots of EcoRI 
digests of HSV-1 (KOS) DNA were probed with the 32P-labeled HCMV BarnHI D 
fragment. Hybridization was observed only with the 4.1 kb HSV-1 EcoRI M 
fragment (Figure 6A). No hybridization was detected between the HSV-1 
EcoRI M fragment and HCMV BarnHI fragments other than D (Figure 6B). 
Southern blots of restriction digests of the HCMV BarnHI D fragment 
were then probed with the 32P-labeled EcoRI M fragment of HSV-1. The probe 
hybridized with the smaller HCMV EcoRI fragment (M), the largest PstI 
fragment (Q), the largest XbaI fragments (B,Q), and the largest BglII 
fragment (M) (Figure 6C). 
Conversely, Southern blots of the HSV-1 M fragment digested with 
KpnI and BarnHI were probed with the radiolabeled HCMV D fragment. 
Hybridization occurred only with the smaller HSV-1 BarnHI fragment and the 
larger HSV-1 KpnI fragment (Figure 6D). The region of homology is shown 
in Figure 7. Although the EcoRI M fragment of HSV-1 also contains part 
of the coding sequences for the major DNA binding protein (104), the 
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Figure 4. Dot blot of processed patient urine samples and HSV and HCMV 
controls hybridized with the combined biotinylated HCMV BamHI D and 
H probes. Rows 1 to 3 columns A through E, contain patient samples. 
Row 4 contains the control virion samples: A, background; B, HSV-1; 
C, HSV-2; D, HCMV AD169; and E, clinical isolate of HCMV. 
probe reactivity with the HSV controls. 
Note the 
1 
2 
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Figure 5. Duplicate dot blots of HSV and HCMV controls hybridized with 
single HCMV BamHI D or H fragment. Dot blots I (left) were 
hybridized with the H probe; dot blots II (right) were hybridized 
with the D probe. Row 1: HSV-1 virion DNA from cell culture 
supernatant: 1-ml (A) and 0.1 ml (B) samples. Row 2: HSV-1 virion 
DNA from cell culture supernatant: 1-ml (A) and 0.1 ml (B) samples. 
Row 3: HCMV AD169 virion DNA from cell culture supernatant: 1-ml (A) 
and 0.1 ml (B) samples. Row 4: HCMV AD169 CsCl-purified DNA: 20-ng 
(A) and 200 pg (B) samples. Note the reactivity of the D probe with 
HSV samples and corresponding lack of reactivity of the same samples 
with the H probe. 
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Figure 6. Southern hybridization analysis showing regions of homology 
between restriction f~agments of HCMV and HSV-1. Left-hand lanes 
in each panel (A through D) show DNA restriction enzyme digests 
electrophoresed in 0. 7% agarose gels and stained with ethidium 
bromide, and right-hand lanes show the corresponding autoradiograms 
of the Southern blots made from the same gels and hybridized with 
32P-labeled probes. Autoradiograms were exposed for 20 h (A and C) 
or 48 h (Band D). (A) Lane 1, EcoRI digest of HSV-1 (KOS) genomic 
DNA; lane 2, hybridization with HCMV AD169 BamHI D fragment. (B) 
Lane 3, BamHI digest of HCMV AD169 genomic DNA; lane 4, 
hybridization with pSG17 (HSV-1 EcoRI M insert). (C) Lanes 5 to 8, 
HCMV AD169 D fragment digested with (left to right): EcoRI, Pstl, 
Xbal, and Bglll, respectively; lanes 9 to 12, hybridization with 
HSV-1 EcoRI M fragment. Faint bands on gel and autoradiogram 
represent partial digestion products. (D) Lanes 13 and 14, HSV-1 M 
fragment digested with BamHI and Kpnl, respectively; lanes 15 and 
16, hybridization with HCMV AD169 BamHI D fragment. Numbers to the 
left of panels C and D are molecular size markers. 
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Figure 7. Restriction endonuclease maps of HCMV AD169 (67)and HSV-1 KOS 
(59). (A)BamHI map of HCMV AD169 showing location of selected probe 
fragments B, D, and H. An expanded map of the D fragment showing 
EcoRI, Bglll, Pstl, Xbal sites is shown below. (B) EcoRI restriction 
map of Hsv-1 (KOS) showing location of the M fragment. An expanded 
map of this fragment is also shown. Enzyme sites are EcoRI (R), Kpnl 
(K), and BamHI (B). The shaded area of the expanded HSV-1 M 
fragment represents the region of homology with HCMV. UL, Long 
unique sequence; Us, short unique sequence; TRL and TRs, terminal 
repeats; IRL and IRS, inverted repeats. 
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region of homology between HSV-1 and HCMV includes only sequences from the 
DNA polymerase open reading frame (104). 
Detection of HCMV with the H fragment probe. Since the H fragment 
did not cross-react with HSV DNA, it was used alone to see whether a 
single fragment would have the same sensitivity as the combined probes. 
A total of 35 urine samples were prepared for detection of HCMV in the 
same manner as the previous specimens, and the samples were hybridized 
with the biotinylated H fragment as the probe. The results are given in 
Table 1. Of 14 culture-positive specimens, 11 were probe positive 
(sensitivity, 78.6%), whereas 5 specimens were probe positive but culture 
negative. One of the latter samples was from a patient whose previous 
specimens had been culture positive. Sixteen specimens were negative by 
both methods. The specificity for this probe was, therefore, 76. 2%. 
Probe and cell culture agreement was 77.1%. 
Although sensitivity and specificity were similar for the combine 
(D and H) and single (H) probes, there was a difference in color intensity 
of the positive samples. None of the samples tested with the H fragment 
alone showed a color reaction greater than plus/minus. With the combined 
probes, on the other hand, there were several samples which showed 2+ or 
greater color reactivity (Figure 4). 
Screening of HCMV recombinant library for sequences homologous to 
HSV-1 TK. The homology discovered between the HSV-1 and putative HCMV 
DNA polymerase sequences prompted a similar search for homology between 
the HSV-1 TK and HCMV. In order to screen dot blots of DNA isolated from 
HCMV recombinant clones for homology to the HSV-1 TK gene, it was 
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necessary to remove the HSV-1 EcoRI N fragment from the vector DNA 
(pBR328) of pSG87 (64). The vector sequences would otherwise hybridize 
to the pBR322 vector sequences of the HCMV recombinants. Small-scale DNA 
preparations from the 67 recombinant clones of the HCMV AD169 library were 
dot-blotted onto nitrocellulose and hybridized with the HSV-1 EcoRI N 
fragment labeled with 32P. After 22 h of hybridization under moderately 
stringent condition, two isolates, numbers 279 and 306, produced a 
stronger signal with the probe than any of the other isolates (Figure 8). 
All of the recombinant samples produced a weak signal, which was probably 
the result of hybridization between small residual amounts of vector DNA 
in the probe preparation and the vector sequences of the HCMV recombinant 
plasmids. 
DNA isolated from the 67 HCMV recombinants was digested with BamHI, 
subjected to agarose gel electrophoresis, and blotted onto GeneScreen Plus 
membranes. The membranes were hybridized with the intact HSV-1 pSG87 
plasmid (64) labeled with 32P. This meant that both vector (pBR328) and 
insert (EcoRI N fragment) were present in the probe. Figure 9 shows the 
results for a representative group of the recombinants including 279 and 
306. The common band in all of the digests represents probe hybridization 
with the pBR322 vector of the recombinants. The other faint bands of 
hybridization do not correspond to any insert bands on the original gels 
(Figure 9C and 9D). There are also faint bands in the gel lanes which 
occur at the same position as the non-vector bands on the autoradiograms, 
but these probably represent undigested or partially digested plasmid DNA 
which still contains vector sequences. The lanes which contain DNA 
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Figure 8. Dot-blot of HCMV strain AD169 BamHI library for detection of 
homology with HSV TK. 
Rows 1-6: Plasmid pBR322 with HCMV BamHI restriction fragment 
inserts. No DNA in positions SL and 6L. Positions 6H,I,J, and K, 
Hindlll fragments A,B,C,D of VZV DNA inserted into the vector pBR322 
(negative controls). 
Row 7: Position 7F, HSV EcoRI N fragment without vector. Position 
7H, pBR322 DNA. Position 7J, 100 ng HCMV AD169 DNA. The blotted 
membrane was hybridized with HSV EcoRI N fragment without vector 
sequences. This fragment contains the coding region for the TK 
gene. Autoradiogram was exposed for 20 h. 
Note: positions 3L and 4G are clone numbers 279 and 306 
respectively. 
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Figure 9: Southern blots of restriction endonuclease digests of HCMV DNA 
cloned fragments to detect homology with HSV TK. 
A and C: Southern blot with corresponding agarose gel. Lanes 1-10: 
BamHI restrictions of HCMV fragments inserted in the BamHI site of 
pBR322. Lane 11: pUC18 plasmid DNA. 
B and D: Southern blot with corresponding agarose gel. All lanes 
contain BamHI restrictions of HCMV fragments inserted in the BamHI 
site of pBR322. 
Blots were hybridized with pSG87 (64) which has HSV EcoRI N fragment 
insert (HSV TK) in the vector pBR328. Autoradiograms were exposed 
for 20 h. 
Note lanes A-10 and B-7 (arrows) contain clone numbers 279 and 306 
respectively. 
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isolated from recombinants 279 and 306 (arrows) are AlO and B7 
respectively. Unlike the dot-blot preparations there are no insert bands 
hybridizing with the intact HSV-1 pSG87 plasmid probe. 
BamHI restriction digests of recombinants 8, 215, 279, 306, and 452 
were performed to try to resolve the conflicting results between the dot-
blots and Southern blots of the HGV recombinants. In addition total 
genomic HCMV DNA was digested with BamHI, HindIII, and XbaI. Southern 
blots of all of these digests were probed with the HSV-1 EcoRI N fragment. 
There was no hybridization with any restriction fragments under moderately 
stringent conditions. The only visible hybridization was to the N 
fragment control (data not shown). 
Since the Southern blots of these selected recombinants failed to 
show hybridization with the HSV-1 probe, dot-blots of newly isolated DNA 
from the same recombinants was hybridized with the same probe (HSV-1 EcoRI 
N fragment without vector). There was no consistent increase in 
hybridization with recombinants 279 and 306 as had been previously 
observed on the original dot-blots (Figure lOD, compare with Figure 8). 
In fact the pBR322 vector control (Figure lOD column Fl,2) had as strong 
a signal as some of the recombinants. 
In order to address the possibility that there was an error in 
applying the HCMV recombinant DNA preparations in the original dot-blot 
(Figure 8), the entire set of HCMV recombinant plasmids was freshly 
isolated and dot-blotted onto nitrocellulose membranes. These dot-blots 
were again probed with the HSV-1 EcoRI N fragment. Figures lOA, lOB and 
lOC show no marked increase in intensity of probe hybridization for any 
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Figure 10. Repeat dot-blots of HCMV strain AD169 BamHI library to detect 
homology with HSV TK (see Figure 8). The probe for all dot-blots 
is the HSV-1 EcoRI N fragment with vector removed. Exposure was for 
24 ,h. 
Panel A: Rows 1-5, plasmid DNA from HCMV library samples. Row 6, 
E, pBR322 DNA; F, HSV-1 pSG87 DNA (positive probe control). 
Panel B: Rows 1-5, BamHI HCMV library samples. lF, clone 279; 3A, 
clone 306 (asterisks). Row 6, same controls as in panel A. 
Panel C: Row 1, plasmid DNA samples from HCMV library. Row 2, A, 
last sample from HCMV library; C-F, Hindlll fragments A,B,C,D of 
VZV (negative controls). Row 3, C 100 ng HCMV DNA. Row 4, E, HSV-
1 pSG87 DNA ; F, pBR322. 
Panel D: Repeat isolates of plasmid DNA from clones which originally 
hybridized with probe (Figure 8) and random negative clones from 
library. Rows 1 and 2: Upper and lower dots in each column are two 
different DNA preparations of each recombinant clone. Columns A-E 
recombinant plasmids in order: 8, 215, 279, 306,and 452. Column F: 
pBR322 vector control. Row 3: B, plasmid pSG87 positive probe 
control. 
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of the samples including 279 and 306, which are both labeled with 
asterisks on dot blot B (lF and 3A respectively) The variability in 
hybridization signal among the recombinants was interpreted to be non-
specific binding of the probe to the DNA samples. 
From these experiments it was concluded that although there was 
homology between the DNA polymerase coding sequences of HSV-1 and a 
specific region of HCMV DNA, there was no evidence that there was homology 
between a fragment encoding the HSV-1 TK and HCMV DNA. 
HCMV AD169 stock for selection of drug-resistant mutants. The BamHI 
D fragment of HCMV DNA had been found to hybridize with a subfragment of 
the HSV-1 EcoRI M fragment (Figures 6 and 7). This evidence plus sequence 
data from two published reports (70, 89) indicates, that the HCMV DNA 
polymerase probably is encoded by a 5. 28 kb subfragment of BamHI D. 
Further evidence that this region encodes the polymerase would be provided 
by mapping mutations which produce resistance to drugs which target the 
DNA polymerase. In order to select for HCMV isolates which have such 
mutations, a sample of HCMV strain AD169 was cultured for large-scale 
production of a "wild-type" stock. 
A three- times plaque -purified frozen sample of HCMV AD169 ( 24/6A/2D, 
harvested 4/30/82) was used to inoculate tube monolayers of HFF at an MOI 
of 0.01. The supernatant fluid was harvested three days after the cultures 
reached 100% CPE. Virus stock from these tubes was frozen in 10% DMSO 
and 10% FCS at -70° C for future use. All experiments to isolate drug-
resistant mutants started with this "wild-type" stock. 
Selection for drug-resistance by plague assay. Mutants of HSV-1 
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resistant to antiviral agents have been selected after a single exposure 
to each agent (23,40). This selection method is most likely to produce 
high-level resistance resulting from single mutations. In order to try 
to isolate similar mutants of HCMV the wild-type AD169 stock was titered 
in the presence and absence of high concentrations of PAA, Aph and GCV. 
The concentration of drug originally used for selection of PAA 
mutants, 700 µM (100 µg/ml), was chosen based on a reported method of 
selection for HSV-1 mutants (40). Only a few small plaques were obtained 
in all of the wells at this concentration. Attempts to pass these plaques 
were not successful. The concentration of drug was lowered to 17S-3SO µM 
(2S-SO µg/ml). PAA even at 17S µM (2S µg/ml) produces a more than 20-fold 
reduction in titer (Table 2), but a few of the plaques which did appear 
in the drug wells were passed to tube monolayers. Two of these tubes 
yielded viable virus, which was retitered. The percent survival of each 
of these plaque isolates (P2SA and PSOA) was no higher than the wild-type. 
The second drug which was used to try to select for resistant 
mutants was Aph. The drug concentrations chosen to titer the stock strain 
were based on similar experiments with HSV-2 (111) and preliminary testing 
of HCMV (6S). Concentrations from l.S to lS µM produced reductions in 
titer ranging from S to 100-fold (Table 2). Plaques were selected from 
wells containing 6 or lS µM and retitered for resistance. Again no 
increased resistance was noted even with three-times plaque-selected 
isolates (see isolates Aph SB/SA/SD and Aph SB/SF/SD in Table 2). 
The third drug used for selection of resistance was GCV. There was 
at least a 100-fold reduction in titer of the wild-type in the presence 
TABLE 2. Selection for drug-resistant mutants from direct plaque isolates. 
Isolate Number Drug Selection Drug Concentration % Survival** 
AD169 PAA 700 µM <<1% 
AD169 PAA 3SO µM <1% 
AD169 PAA 17S µM 4.4% 
AD169 PAA 87. S µM 30% 
P2SA PAA 140 µM 2.S% 
PSOA PAA 140 µM 2.3% 
AD169 Aph lS µM <1% 
AD169 Aph 6 µM S.S% 
AD169 Aph l.S µM 22.S% 
Aph SC Aph lS µM <1% 
Aph SD Aph lS µM <1% 
Aph SB/SA/SD Aph lS µM <1%* 
Aph SB/SF/SD Aph lS µM <1%* 
AD169 GCV 100 µM <1% 
AD169 GCV so µM <1% 
AD169 GCV 2S µM <1% 
AD169 GCV 12.S µM 14% 
TABLE 2. (Continued) 
D25B 
D12B 
D12A/50A 
D2SB/12A 
Dl2B/25A/12B 
D12B/25A/12C 
Dl2B/25A/12D 
GCV 
GCV 
GCV 
GCV 
GCV 
GCV 
GCV 
*Plaque-selected three times. 
** Titer with drug x 100 
Titer without drug 
12 .5 µM 
12.S µM 
12. 5 µM 
12. 5 µM 
12. 5 µM 
100 µM 
100 µM 
10% 
22% 
7.6% 
21.4% 
17.6%* 
<1%* 
<1%* 
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of 25 µM GCV (Table 2). Individual plaques which did appear at that 
concentration were passed to tube monolayers and cultured in the absence 
of drug. Viral progeny from these tubes were retitered in the presence 
and absence of GCV. Percent survival of plaque-selected isolates was 
essentially the same as the wild-type AD169 at both low (12.5 µM) and high 
(100 µM) concentrations of drug. For example in Table 2 isolate D25B was 
an initial plaque isolate with a 10% survival in 12.5 µM GCV. Isolates 
Dl2B/25A/12C and Dl2B/25A/12C were plaque-selected three times, but the 
percent survival at 100 µM GCV was still less than 1%. 
Whenever one of these three drugs (GCV, PAA, Aph) was present in 
the culture medium at low concentration, the plaques were smaller than 
those produced in the absence of drug. With GCV and PAA the cells within 
the plaques were large and usually syncytial. Cells remained attached to 
the monolayer surface, and initial foci of infection enlarged only 
slightly during the course of the assay (14-18 days). At the higher drug 
concentrations no plaques were formed and only rare single enlarged cells 
were observed. 
Selection for resistant mutants in increasing concentrations of 
antiviral agents. A second method for selection of resistant mutants was 
to expose the wild-type stock to increasing concentrations of antiviral 
agents. Individual tube monolayers were inoculated with wild-type HCMV 
AD169 virus stock. The virus was propagated initially in the presence of 
low concentrations of each of the three antiviral agents PAA, Aph or GCV. 
Each tube monolayer was passed to a new monolayer, whenever there was 
close to 100% CPE, or the monolayers were too old to support further viral 
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replication. The time between passages was usually at least two weeks but 
often 4-6 weeks. The progeny of each of the original tubes were always 
kept separate, so that any potential mutants would represent individual 
mutational events. 
The initial concentration of PAA was 140 µM (20 µg/ml). The 
monolayers were incubated at this concentration up to 4 weeks. If the 
CPE was less than 100% after this time, the monolayers were passed to new 
monolayers, and the same concentration of drug was added to the culture 
medium. If 100% CPE was observed before 4 weeks of culture, the monolayers 
were passed to new monolayers, and the concentration of PAA was increased 
by a 10 µM increment. Eventually after 8-10 passages, there was close to 
100% CPE in three tubes which had been exposed to 700 µM (100 µg/ml) PAA. 
When the extracellular virus was retitered at 700 µM PAA, however, the 
percent survival was less than 10%. Although these isolates may be 
slightly more resistant to PAA than the wild-type, this does not represent 
high-level resistance. The CPE may have been the result of passage of 
virus monolayers at a high MOI, which increases the apparent level of 
resistance to antiviral agents (see effect of MOI on GCV mutants measured 
by ELISA below) . 
Aphidicolin above 7.5 µMis slightly toxic for uninfected HFF. Five 
tubes were inoculated with HCMV AD169, and Aph at a concentration of 1.5 
µM was added to the cell culture medium. The same protocol was followed 
for passage of monolayers as described above for PAA selection, except 
that the levels of increasing drug concentration were 6, 7.5 and 15 µM. 
The number of passages at each drug concentration was usually 3 to 4, and 
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the total number of passages was 8 to 10. One of the original 5 tube 
lines initiated for selection of resistance to Aph retained evidence of 
viral infection at a 15 µM concentration, but there was never 100% CPE, 
and only monolayers could be passed for infectivity. 
The only drug selection which yielded high-level resistant virus was 
GCV. For GCV selection the frequency of passage of monolayers again 
depended on the amount of CPE up to 4 weeks of culture. The initial 
selection was at a drug concentration of 6. 25 µM. The levels for 
increasing the concentration of drug were 10, 12.5, 25, 50 and 100 µM. 
Virus from three of the original 10 tube lines produced 100% CPE at 25 µM 
GCV. These virus lines were spontaneously able to produce 100% CPE at 50 
and 100 µM. High-level resistance, therefore, was achieved after exposure 
to 25 µM GCV. 
Each of these three GCV-resistant strains of HCMV AD169 was plaque-
purified three times. One plaque-purified sample from each strain was 
selected for further characterization. These isolates are designated 
D6/3/l, Dl/3/4 and Dl0/3/2. All three GCV-resistant mutants produce true 
plaques which enlarge during the period of culture in the presence of the 
drug. The plaques are slightly smaller and slightly slower to appear when 
the drug is present, but both D6/3/l and Dl/3/4 have extracellular titers 
equivalent to the wild-type in the absence of GCV. Dl0/3/2 appears to 
replicate to lower extracellular titer than the wild-type in the absence 
of drug, and the plaque morphology differs from both the wild-type and the 
other mutants in appearing more syncytial. The relative reduction in 
titer of Dl0/3/2 in the presence of GCV, however, is no greater than that 
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of the other two mutants (see below). 
Resistance of wild-type and GCV-resistant mutants to other antiviral 
£!_gents measured by plague dilution. Table 3 summarizes the cross -
resistance of the three GCV-resistant mutants to other antiviral agents 
measured by percent survival. All three mutants were equally sensitive 
to relatively high concentrations of PAA, Aph and ACV. All three mutants 
were slightly more sensitive to AraA compared to the wild-type, but this 
hypersensitivity was less than four-fold. GCV is the only antiviral agent 
to which the mutants are much more resistant than the wild-type. 
One problem in determining percent survival is that the wild-type 
does not form plaques in the presence of GCV at higher dilutions of the 
stock. Instead only isolated enlarged cells appear in the monolayer. 
The titer of AD169 in the presence of GCV, therefore has been recorded as 
the highest dilution in which only rare single infected cells are present. 
These individual cells are probably abortively infected, since adjacent 
cells never appear to be infected. Counting these enlarged cells as 
plaques means that the calculated titer based on number of plaque forming 
units (pfu) in the presence of GCV is probably too high. Thus, an 
accurate measurement of percent survival for the wild-type is difficult 
to determine by this method. 
Resistance of mutants and wild-type AD169 measured by plaque 
reduction. A second method which was used to determine the relative 
resistance of both mutant and wild-type HCMV strains to antiviral agents 
was plaque reduction. To perform the assay a dilution of each virus 
strain containing 30 to 50 pfu was inoculated on monolayers in 24-well 
TABLE 3. Percent survival of AD169 and mutants. 
AD169 
06/3/1 
Dl/3/4 
Dl0/3/2 
Ganciclovir 
(100 µM) 
<l* 
85 
77 
72 
AraA 
(150 µM) 
33 
9 
10 
4 
*Values are Titer with drug 
Titer without drug 
PAA 
(700 µM) 
<1 
<1 
<1 
<1 
x 100. 
Aph 
(15 µM) 
<1 
<1 
<1 
<1 
ACV 
(300 µM) 
6 
12 
14 
14 
Titers were determined by plaque dilution assay. 
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plates. The overlay medium contained serial two-fold dilutions of the 
drug. The ID50 was determined by the micromolar concentration of each 
antiviral agent which reduced the number of plaques by 50% relative to 
controls without the antiviral agent. The results of these assays are 
summarized in Table 4. All of the mutants were equally sensitive or 
resistant to GCV, PAA, Aph, and ACV. The mutants appeared again to be 
slightly hypersensitive to AraA compared to the wild-type. The mutant 
D6/3/l was no more resistant to PFA than the wild-type but was slightly 
hypersensitive to AraT, FIAC and FIAU. 
Since this assay also involves counting plaques, the same apparent 
wild-type abortive infection that is observed in plaque dilution assays 
is a problem. Even at the lowest drug concentration of GCV (6.25 µM), 
the size of the wild-type plaques was significantly reduced compared to 
those produced by the mutants. 
Resistance of mutants and wild-type AD169 measured by ELISA. The 
problems encountered with counting wild-type plaques in the presence of 
GCV were addressed by using a third method to measure antiviral drug 
resistance. Both the percent survival and plaque reduction assays may 
have overestimated the titer of the wild-type in the presence of GCV. 
In order to perform the ELISA, monolayers in 96-well microtiter 
plates are infected with the HCMV strain at an MOI of 0.01. Replication 
is allowed to proceed until the virus control wells show approximately 
50% CPE (2+). This usually takes 4 to 5 days post- infection. The 
monolayers are then fixed to the bottom of the microtiter plate wells. 
Primary murine monoclonal antibody to an HCMV late antigen (see ELISA 
TABLE 4. Plaque reduction assays. 
GCV AraA PAA Aph ACV PFA FIAC FIAU AraT 
AD169 S* lSO 180 6 lSO 200 4 10 1,000 
D6/3/l lSO so 180 6 lSO 200 1. s s 290 
Dl/3/4 >100 so 180 6 lSO 
Dl0/3/2 >100 so 6 7S 
*Values are the micromolar concentrations of each antiviral 
agent which reduce the number of plaques by SO% relative to 
controls without the antiviral agent. 
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section of Materials and Methods) is added to the fixed infected monolayer 
followed after a period of incubation with a secondary antibody, which is 
tagged with horse radish peroxidase. A substrate for horse radish 
peroxidase is added after another period of incubation and a colored 
product results from enzyme activity on the substrate. The amount of 
color is measured spectrophotometrically and is related to the amount of 
viral antigen produced. Inhibition of viral replication by GCV is 
measured by a reduction in optical density in virus-infected wells 
containing GCV in comparison to virus-infected control wells. The ELISA 
endpoint is the drug concentration producing a 50% reduction in the 
optical density (OD50 ) of colored product. The main purpose of this assay 
was to confirm the previously observed sensitivity of the wild-type to 
GCV, which was difficult to quantitate by the other two methods described 
above. Only one of the mutants, D6/3/l was tested by this method. The 
endpoints of the wild-type and D6/3/l for GCV were very similar to those 
obtained by the plaque reduction assay. 
hypersensitive to AraA (Table 5). 
The mutant was also 
The advantage of the ELISA is that production of the viral late 
antigen is detected colorimetrically. This measurement is proportional 
to the actual amount of virus replication within each cell, because the 
production of late antigen requires viral DNA replication. Plaque assays 
measure the ability of an infectious particle to produce additional 
infectious progeny, which in turn infect adjacent cells. In comparison 
with plaque assays the ELISA should more accurately reflect the amount of 
virus produced by the wild-type within the large single infected cells 
TABLE 5. Resistance to antiviral agents determined by ELISA. 
AD169 
06/3/l 
GCV AraA PAA Aph 
3* 125 45 2 
125 50 45 2 
*Values are the micromolar concentrations which cause 
50% reduction of optical density of colored substrate. 
-....J 
00 
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which are observed in the presence of GCV. 
It should be noted, however, that the actual value of the 50% 
endpoint in the ELISA is dependent on the MOI. In Figure 11 the effect 
of increasing MOI on the OD50 is demonstrated for both mutant and wild-
type. The OD50 of the wild-type is approximately 1 µM at an MOI of 0.01 
and 20 µMat an MOI of 0.1. At the lower MOI of the mutant D6/3/l the 
0050 is approximately 80 µM while the OD50 at the higher MOI is 
approximately 190 µM. Even at the highest MOI, however, the level of 
resistance of the mutant is close to 10-fold higher than that of the wild-
type. 
Analysis of restriction enzyme digests of mutant and wild-type 
genomic DNA. The assays for cross-resistance of the GCV-resistant mutants 
to other antiviral agents did not provide any evidence for a mutation in 
the DNA polymerase gene. In order to investigate the possibility of a 
polymerase mutation further, virion DNA was isolated from the wild-type 
and the three mutants D6/3/l, Dl/3/4 and Dl0/3/2. The samples of DNA were 
digested with EcoRI, PstI, HindIII or Bglll. Southern blots of the 
digests were hybridized with a plasmid containing the EcoRI M restriction 
fragment inserted into the vector pUC18. The EcoRI M fragment hybridizes 
with the HSV-1 DNA sequences which encode the HSV-1 DNA polymerase 
(89,97). No differences in the positions of the bands hybridizing with 
the probe were noted for any of the enzyme digests (Figure 12). The probe 
hybridized with fragments of the predicted size (Figure 2) in all digests. 
On some gels on which the restriction enzyme patterns of all three 
mutants were compared to that of the wild-type, an extra restriction 
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Figure 11. Effect of MOI on OD50 for GCV. Upper graph, wild- type AD169. 
Lower graph, mutant D6/3/1. 
Squares, MOI=O.l; triangles, MOI=0.01. 
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Figure 12. Southern blot with corresponding agarose gel of restriction 
endonuclease digests of DNA from mutant Dl0/3/2, Dl/3/4, and D6/3/l 
and ~ild-type AD169 to detect restriction site polymorphism in the 
DNA polymerase gene. 
Lanes A, F, K, and P: AD169 DNA. 
Lanes B, G, L, and Q: Dl0/3/2 DNA. 
Lanes c, H, M, and R: Dl/3/4 DNA. 
Lanes D, I, N, and S: D6/3/l DNA. 
Lanes E, J, 0, and T: EcoRI M fragment of AD169 inserted in pUC18. 
Restriction enzymes used for digestion were as follows: Lanes A-E 
EcoRI; lanes F-I Pstl; lane J Pstl and Ecol; lanes K-N HindIII; lane 
0 Hindlll and EcoRI; lanes P-S Bglll; lane T Bglll and EcoRI. 
Probe for Southern blot was HCMV AD169 EcoRI M fragment inserted in 
pUC18. Exposure time of autoradiogram was 24 h. 
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fragment of about 2 kb in size was noted in the BglII digests of the 
mutants (see lower left gel in Figure 13). The intensity of the fragment 
was less than that of the majority of bands in the digest suggesting that 
it might represent a new terminal fragment which is present in less than 
1 M concentration. In order to test this hypothesis Southern blots of 
BglII digests (Figure 13) were hybridized with plasmids containing BamHI 
restriction fragment J (see Figure 2). This fragment contains terminal 
(isomeric inversion see Figure 1) and junction sequences surrounding the 
short unique region of the genome. The probe hybridized with this new 
fragment (Figure 13 autoradiogram) as well as to the large fragments at 
the top of the gel. These large bands are the junction fragments, which 
span the repeat regions of both the U5 and UL segments of the genome. 
These bands would be expected to hybridize with the probe, because they 
contain the common repeat sequences. 
There are two other slightly larger fragments which hybridized with 
the probe. These bands may contain some of the repeat sequences in common 
with the probe and may represent additional variation in restriction bands 
in the repeat region. This part of the HCMV genome has been shown to be 
the most variable among HCMV strains (90,126). 
Further investigation of the extra BglII restriction fragment in 
the mutants, demonstrated, however, that the fragment is associated with 
the source of the viral DNA. The sample of AD169 DNA which had been 
analyzed with the mutant DNAs in Figure 13 (lane 2), was purified from 
intracellular DNA. When a sample of extracellular wild-type virion DNA 
was digested with BglII, the extra restriction band was present in the 
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Figure 13. Analysis of Bglll restriction site polymorphism of mutant and 
wild-type AD169 DNA. 
Southern blot (upper figure): lane 1, intracellular AD169 DNA 
digested with BamHI; lane 2, intracellular AD169 DNA digested with 
Bglll; lane 3, extracellular D6/3/l DNA digested with BglII; lane 
4, extracellular Dl0/3/2 DNA digested with BglII; lane 5 
extracellular Dl/3/4 DNA digested with BglII; lanes 6 and 7, 
extracellular AD169 DNA digested with Bglll; lane 8 pSG87 (HSV-1 
EcoRI N fragment, vector pBR328) digested with Bglll; lane 9 plasmid 
containing HCMV EcoRI D fragment in vector pUC18 digested with 
EcoRI. Probe was HCMV AD169 recombinant clone nwnber 279 which has 
BamHI J fragment inserted into pBR322. 
autoradiogram was 24 h. 
Exposure time for 
Agarose gel (lower left): corresponding gel for 
above. 
Southern blot 
Agarose gel (lower right): Lane 1, extracellular AD169 DNA ; lane 
2, intracellular AD169 DNA; lane 3, extracellular D6/3/l DNA; lane 
4 extracellular Dl/3/4 DNA; lane 5 HSV-1 pSG87 (EcoRI N fragment, 
TK); lane 6, lambda DNA. Lanes 1-4 were digested with Bglll, lane 
5 with EcoRI and lane 6 with HindIII. 
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wild-type digests as well as the mutants (Figure 13 lower right gel). 
There is extracellular AD169 DNA digested with BglII in lanes 6 and 7 of 
the lower left gel in figure 13. The concentration of DNA is too low to 
visualize the extra BglII band, but on close examination of the upper 
auto radiogram, faint bands co-migrating with the hybridization bands in 
lanes 3 through 5 can be seen. Therefore, this band is found in 
extracellular DNA in both mutant and wild-type strains and does not 
represent an altered restriction site that could be associated with GCV 
resi stance . 
HPLC analysis of drug anabolism of the GCV-resistant mutants. 
Neither cross-resistance to other antiviral agents nor restriction 
fragment polymorphisms provided any suggestion as to the site of the 
mutation responsible for GCV resistance . Biron et al. ( 4) used ion 
exchange HPLC to demonstrate that their GCV -resistant mutant of HCMV AD169 
was unable to phosphorylate the drug. 
In order to analyze the GCV anabolism by D6/3/l, Dl/3/4 and Dl0/3/2, 
a reversed phase HPLC system was deve loped. Unlabeled GCV and GCV-
monophosphate (a gift from Syntex) were used as standards to determine 
retention times and drug stability under the conditions required for 
sample preparation. No standards for the di- and tri-phosphates of GCV 
were available, but it was assumed that these compounds would be more 
polar than the monophosphate, and therefore , would have shorter retention 
times. 
On the Partisil ODS-3 column with a mobile phase of 0.02 M KH2P04 , 
GCV-monophosphate had a retention time be tween 4.5 and 5.0 min depending 
88 
on the flow rate, which was either 1.5 or 2.0 ml/min. The retention time 
for GCV under the same conditions was between 10 and 11 min. Two 
different perchloric acid extraction methods were tested. When both 
standards were exposed to 0.5 M perchloric acid for several hours at room 
temperature, the unmodified drug was unstable, but the monophosphate was 
unaffected. When perchloric acid extracts were neutralized with KOH, only 
the monophosphate was unstable. In order to avoid degradation of either 
GCV or GCV-monophosphate, infected cell monolayers which had been labeled 
with 3H-GCV (Syntex), were washed and resuspended in a small volume of DPBS 
and extracted in a 200 µl volume at a final concentration of 0. 5 M 
perchloric acid. The samples were then analyzed immediately by HPLC. If 
necessary, the samples were stored briefly at -70° C. 
The analysis of labeled cell extracts was repeated three times, and 
the results were the same for each virus strain. Uninoculated control 
cells had low counts in fractions 34-37, which represent unphosphorylated 
drug (Figure 14). The early fractions collected up to five minutes 
(Fractions 8-18) have very few counts above background, therefore, there 
is very little phosphorylation of GCV by uninfected cells. The same 
analysis of wild-type AD169 infected cells showed very high peaks for both 
unphosphorylated GCV (fractions 34-37) and its phosphorylated derivatives 
(fractions 8-18) (Figure 15). By contrast all three mutants have much 
lower peaks corresponding to the retention times of the phosphorylated 
derivatives (fractions 8-18 in Figures 16 through 18). From these results 
it can be concluded that AD169 phosphorylates GCV as predicted, while the 
mutants do not phosphorylate GCV to any great extent. Since mono-
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Figure 14. HPLC analysis of GCV anabolism in uninfected HFF cells. 
Fractions were collected at O. 3 min intervals over a Partisil ODS3 
reversed phase column. The flow rate was 1.5 ml/min. The mobile 
phase was 0. 02 M KH2Po4 . Fractions 8-18 correspond to the retention 
times of phosphorylated derivatives. 
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Fi~ure 15. HPLC analysis of GCV anabolism in AD169-infected cells. HPLC 
conditions were the same as in Figure 14. Fractions 8-18 correspond 
to retention times of phosphorylated derivatives of GCV. 
Unphosphorylated drug fractions are 34-37. 
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Figure 16. HPLC analysis of GCV anabolism in mutant D6/3/l-infected 
cells. HPLC conditions were the same as in Figure 14. Fractions 
8-18 correspond to the retention times of phosphorylated derivatives 
of GCV. Unphosphorylated drug fractions are 33-38. 
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Figure 17. HPLC analysis of GCV anabolism in mutant Dl/3/4-infected 
cells. HPLC conditions were the same as in Figure 14. Fractions 
8-18 correspond to the retention times of phosphorylated derivatives 
of GCV. Unphosphorylated drug fractions are 33-38. 
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Figure 18. HPLC analysis of GCV anabolism in mutant Dl0/3/2-infected 
cells. HPLC conditions were the same as in Figure 14. Fractions 
8-17 correspond to retentions times of phosphorylated derivatives 
of GCV. Unphosphorylated drug fractions are 31-35. 
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phosphorylation is necessary to activate the drug intracellularly, the 
increased resistance of the mutants to GCV can be attributed to the 
altered anabolism. 
Analysis of GCV anabolism in co-infected cells. The interaction of 
wild-type and mutant D6/3/l in co-infected cells was investigated next. 
HFF were co- infected with AD169 and D6/3/l at an MOI of 1. 0 for each 
virus. Control flasks were also infected with either AD169 or the mutant 
alone at an MOI of 2. 0. The cultures were pulsed with 3H-GCV at 72 h post-
infection, and the cells were harvested 24 h later. The infected cells 
were extracted with perchloric acid and the extracts were analyzed by 
reversed phase HPLC. In Figure 19 the wild-type and mutant controls, each 
at an MOI of 2.0, are compared. The profiles are consistent with the 
previous HPLC analysis where drug anabolism by the mutant occurs at a much 
lower level than that of the wild-type. In the upper graph in Figure 20 
the wild-type AD169 control at an MOI of 2.0 is compared to co-infected 
cells for which the total MOI was 2.0, but the MOI of each individual 
virus was 1.0. Drug anabolism in co-infected cells in this experiment was 
approximately 10-fold lower than that of the wild-type. The experiment 
was repeated except that the AD169 control was infected at an MOI of 1.0 
instead of 2.0. The HPLC profiles were similar to those in the previous 
experiment, but as might be predicted from the Poisson distribution, the 
number of counts in the GCV and GCV-derivative peaks of the wild-type 
AD169 control were lower. At an MOI of 2.0 the percent of uninfected 
cells would be predicted to be 13. 5%, while at an MOI of 1. 0 the 
percentage of uninfected cells would be expected to increase to 36.8%. 
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Figure 19. HPLC analysis of AD169 and mutant D6/3/l controls for co-
infection experiment. Cell monolayers for each control were 
infected at an MOI of 2.. HPLC conditions were the same as for the 
anabolic studies in Figures 14-18 (phosphorylated derivatives of GCV 
in fractions 7-17, unphosphorylated GCV in fractions 32-37). 
Cross-hatched bars, AD169 control. 
Solid bars, D6/3/l control. 
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Figure 20. HPLC analysis of GCV anabolism in co-infected cells. Upper 
graph: Cell monolayer was co-infected at an MOI of 1.0 for each 
virus (total MOI=2). HPLC conditions same as for anabolic studies 
in Figures 14-18 except the flow rate was 2.0 ml/min. 
Phosphorylated derivatives of 
unphosphorylated drug in fractions 
GCV in 
32-37. 
fractions 7-17, 
Control monolayer 
infected with AD169 at an MOI of 2.0. Lower graph: same as above 
except AD169 control monolayer infected at an MOI of 1.0. 
Cross-hatched bars, AD169 control. 
Solid bars, co-infected cells. 
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As the nwnber of uninfected cells increases, the amount of 
phosphorylation, and therefore the nwnber of counts associated with 
phosphorylated derivatives, decreases. The GCV derivative fractions, 
however, still had more than twice the counts as the corresponding 
fractions in the co-infected cell samples (Figure 20 lower graph). 
The wild-type "kinase" would be predicted to be dominant over the 
mutant, if there is no interaction between the enzymes when they are 
present in the same cell. These experiments demonstrate that the mutant 
activity does have an effect on the wild-type, because the total level of 
GCV phosphorylation in co-infected cells is greatly reduced compared to 
the wild-type control. 
In vitro translation of mRNA from virus-infected cells. From the 
previous HPLC analysis it is apparent that a viral mutation produces an 
alteration in the kinase activity which is responsible for the 
phosphorylation of GCV in virus-infected cells. This suggests that either 
the virus encodes the enzyme for this function or that there is a viral 
product which modifies a cellular kinase. Work by Preston (124) with the 
HSV TK demonstrated that it is possible to obtain a functional protein by 
in vitro translation of RNA isolated from HSV-1-infected cells. A similar 
set of experiments was designed to try to express the GCV kinase function 
in vitro. 
Tritiated-GCV or 14C-labeled-GCV was added to translation products 
from mRNA isolated from cells 72 h post-infection with either wild-type 
AD169 or mutant D6/3/l. In the initial experiments the pH of the reaction 
was 7.5, and the period of incubation for expression of enzyme activity 
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was 5 h. The reason for choosing this pH was that Biron and co-workers 
(5) had used pH 7.5 in attempts to express kinase activity from infected 
cell extracts. The products of the in vitro translation reaction were 
extracted with perchloric acid and the extracts were analyzed by HPLC. 
The conditions for the HPLC analysis were the same as those for the 
studies of GCV anabolism (Figures 14-18). There was no peak corresponding 
to phosphorylated derivatives of GCV from wild-type infected cells (Figure 
21, upper graph). The pH of the reaction was changed to 6 .1 for the 
second set of experiments, and the incubation was increased to 11 h, but 
the results were the same (Figure 21, lower graph). This lower pH was 
used in experiments by Preston (124) for expression of HSV-1 TK activity. 
Since GCV is a substrate for the HSV-1 TK, the optimal reaction conditions 
of the "GCV kinase" might be similar. 
The in vitro translation reactions produced proteins, because the 
same mRNA preparations were used in the analysis of infected-cell proteins 
by 2-dimensional gel electrophoresis as described below, and consistent 
discrete spots were present on all fluorograms of these gels. The lack 
of detectable kinase activity is assumed to be the result of either low 
specific activity label or suboptimal conditions for enzyme activity or 
both. 
Cosmid cloning of D6/3/l DNA. Marker transfer would be a definitive 
method for mapping the enzyme function lacking in the mutants (117). DNA 
was isolated from extracellular virions of D6/3/l and partial BamHI 
restriction fragments were cloned in the cosmid vector pWE15 (Stratagene). 
Over 500 ampicillin-resistant colonies were obtained and 120 of these were 
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Figure 21. HPLC analysis of GCV anabolism following incubation with 
products of in vitro translation of mRNA. 
Upper graph: Analysis of GCV anabolism following incubation with in 
vitro translation products of mRNA isolated from uninfected (cross-
hatched bars) and AD169-infected (solid bars) cells. HPLC 
conditions were the same as for co-infection studies in Figure 20. 
The pH of the expression reaction was 7. 5 and the period of 
expression was 5 h. 
Lower Graph: Analysis of GCV anabolism following incubation with in 
vitro translation products of mRNA isolated from mutant D6/3/l 
(cross-hatched bars) and AD169-infected (solid bars) cells. HPLC 
conditions were the same as for the co-infection studies in Figure 
20. The pH of the expression reaction was 6.1, and the time of 
expression was 11 h. 
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subjected to plasmid DNA analysis. The DNA from each isolate was digested 
with BamHI to determine the size of the fragments present in the cosmid. 
In addition the DNA was blotted and probed with AD169 cosmids obtained 
from Bernhard Fleckenstein (51) or previously cloned fragments of AD169 
DNA (97). Cosmid inserts were identified by fragment size and 
hybridization pattern. Figure 22 shows a group of mutant cosmids, which 
were hybridized with two different known AD169 cosmids to identify the 
region of the genome represented in the mutant. The same blot was first 
hybridized with cosmid 1075 which spans the HindIII R to L fragments. The 
membrane was stripped and then rehybridized with cosmid 1106, which spans 
the HindIII L through D fragments. The mutant cosmids were derived from 
BamHI partial digests of D6/3/l DNA, while the wild-type cosmid probes are 
composed of HindIII partial digestion produces. Note all cosmids have 
different hybridization patterns with the two probes except those in lanes 
14 and 15. The cosmid in lane 14 was found on further study to have non-
contiguous fragments, and the cosmid in lane 15 appeared to have 
rearranged vector sequences in addition to HCMV DNA inserts. Note there 
is no band in lane 15 which migrates with the common vector band (upper 
autoradiogram) in all of the other digests. The hybridization in the 
lambda lanes (1 and 17) results from the common cos sequences present in 
the pHC79 cosmid vector of the probe. 
Eight cosmids were selected for more extensive analysis to see if 
the entire genome was represented. These eight cosmids were chosen, 
because they all had different restriction patterns and different patterns 
of hybridization with the HCMV AD169 cosmid probes. It is difficult to 
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Figure 22. Southern blot of restriction endonuclease digestions of cosmid 
clones of HCMV mutant D6/3/l DNA. The same blot was hybridized 
first with AD169 cosmid 1075 (ref. 51) (upper autoradiogram). The 
probe was then stripped, and the blot was hybridized with AD169 
cosmid 1106 (ref. 51) (lower autoradiogram). Lanes 1and17 of both 
autoradiograms, lambda DNA digested with HindIII. Hybridization of 
lambda fragments with the probe results from the lambda £Q§. site, 
which is part of the cosmid probe construct. The vector portion of 
the AD169 cosmid probes is pHC79. The vector for the D6/3/l cosmids 
is pWE15 (Stratagene). Lane 18 of both autoradiograms, pWE15 DNA, 
restricted with BamHI (single site). Lanes 3-16 of both 
autoradiograms, cosmid D6/3/l DNA restricted with BamHI. 
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analyze cosmids which span any of the repeat regions, since the wild-type 
cosmid probes will hybridize with any fragments containing common repeat 
sequences regardless of the attached unique sequences (see Figure 2). 
Since there are four isomeric forms of the virus, smaller probes are 
required to determine which conformation is present in a given cosmid. 
Smaller probes were not available for this region without extensive 
subcloning. For this reason extra cosmids with different restriction 
patterns, which hybridized with repeat regions of the genome were selected 
to try to ensure, that all repeat and junction regions were included. 
From the somewhat superficial analysis of these eight cosmids, it would 
appear that most, if not all, of the genome is represented. 
The DNA from each of these cosmids was used for a series of 
transfection experiments. Each experiment was set up as follows: 1) In 
the first experiment cosmid DNA was co-transfected with AD169 purified 
virion DNA. In addition some monolayers were transfected with cosmid DNA 
and then infected with wild-type virus. After 48 h 20 µM GCV was added 
to the cell culture medium. Monolayers were passed to new monolayers in 
tubes of flasks and selected with 100 µM GCV. 2) In the second experiment 
all monolayers were transfected with cosmid DNA and infected with wild-
type virus after 24 h. GCV (100 µM) was added after another 24 h. 
Infected monolayers were passed to new monolayers after 5 to 7 days and 
again incubated with 100 µM GCV. 3) In the third experiment some of the 
monolayers were infected first with AD169 and transfected after 2 h. GCV 
was added after 22 h. The remaining monolayers were transfected first 
with cosmid DNA and infected after 22 h with AD169. After a 2-hour 
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adsorption period, GCV (100 µm) was added to the cell culture medium. 
Monolayers were passed to tubes and flasks at 5 to 7 day intervals. The 
cell culture medium always contained 100 µM GCV. 
The reason for combining infection with transfection is that it is 
difficult to transfect the intact AD169 genome because of its large size, 
and it is also difficult to obtain large quantities of purified virion 
DNA. The disadvantage of supplying the wild-type DNA in the form of 
infectious virus is that there is a high background of wild-type CPE, 
which must be titered on new monolayers to test for recombinant virus. 
The order of transfection and infection was varied to see if either method 
might be more efficient for producing resistant virus. 
In all three experiments tubes and flasks were held 4 to 6 weeks 
and repeatedly checked for plaque development. No resistant virus plaques 
were detected in any of the three experiments, although single enlarged 
cells often persisted after passage to successive new monolayers. 
Two-dimensional gel electrophoresis. Since it was possible to 
obtain in vitro translated products from mRNA isolated from virus-infected 
cells, these products were analyzed by 2-dimensional gel electrophoresis. 
The proteins were labeled with 35S-methionine and subjected to 
isoelectrofocusing in the first dimension and SDS-PAGE in the second. It 
is possible that there is a point mutation in D6/3/l, which is responsible 
for the altered kinase activity. Isoelectrofocusing would detect a change 
in isoelectric point resulting from a single amino acid change or possibly 
a small deletion. Point mutations which result in premature stop codons 
or frameshifts would be expected to produce lower molecular weight 
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proteins. A second possibility would be that the proteins might be 
unstable and would not be detected on the gels. Deletions, if large 
enough, would change the molecular weight of the protein. 
Comparison of 2-dimensional gels of mutant and wild-type in vitro 
translation products did not reveal any consistent protein change between 
the two strains. The majority of proteins were consistently present on 
all fluorograms. There were occasional quantitative or qualitative 
changes which were not reproducible. Technical variations in 2-
dimensional gel electrophoresis may contribute to the lack of 
reproducibility. 
Comparison by 2-dimensional gel analysis of proteins extracted from 
mutant and wild-type-infected cells, however, revealed a protein which was 
present in wild-type-infected cells but missing in the mutant-infected 
cells. The arrows in Figure 23 indicate the position of the protein. The 
estimated molecular weight of this protein is 43,000. 
Both the wild-type AD169 and mutant D6/3/l stocks were extensively 
tested for mycoplasma contamination to eliminate the possiblity, that the 
protein could be of mycoplasmal origin. The tests included Hoechst 
staining, monoclonal antibody specific for M. hyorrhinis, and culture of 
both cells and cell culture fluid. All test results were negative. 
The experiment was repeated two more times, and the same protein 
difference appeared on the fluorograms. The protein was not present in 
either uninfected HFF cells or in mutant Dl/3/4-infected cells (data not 
shown). 
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Figure 23. Fluorograms of 2-dimensional gels of proteins extracted from 
AD169-infected cells (A) and D6/3/l-infected cells (B). Proteins 
were labeled 48 h post-infection with 35S-methionine and harvested 
for gel analysis 72 h post-infection. Arrows indicate position of 
43,000 MW protein present in AD169, missing in mutant D6/3/l. 
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DISCUSSION 
There were several significant findings from the experiments 
performed for this project. First of all DNA probes were found to be 
capable of direct detection of HCMV in clinical specimens. Coincidentally 
one of the probes cross-hybridized with the region of the HSV-1 genome 
which encodes the HSV-1 DNA polymerase. Since the HCMV DNA polymerase had 
not yet been mapped, this observation was a significant piece of evidence 
for the location of the polymerase on the HCMV genome. 
Drug-resistant mutants have been very useful for analyzing the DNA 
polymerase locus of HSV. However, there have been very few HCMV mutants 
of any kind reported to date (4,33,34). Three mutants of HCMV (D6/3/l, 
Dl/3/4 and Dl0/3/2), which are resistant to GCV were isolated. These 
mutants were found by HPLC to be deficient in intracellular anabolism of 
GCV. Since GCV must be activated by phosphorylation, the phenotype of the 
mutants suggested that there is a viral function required for this 
activation. No HCMV virus encoded TK has yet been found, although GCV is 
a substrate for the HSV-1 TK. 
Detection of a protein in wild-type infected cells, which is absent 
in D6/3/l- and Dl/3/4-infected cells is probably the most significant 
finding of this investigation. No kinase activity has yet been 
demonstrated for this protein, but the MW (43,000) and the temporal 
appearance (early post-infection) are similar to those of the HSV-1 TK. 
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Development of DNA probes. The biotinylated probes developed for 
this project were each able to detect HCMV in clinical specimens, provided 
that enough viral DNA was available to be detected by probe hybridization. 
Control experiments (Figure 3) indicated that the limit of detection was 
around 30 pg for totally homologous DNA. The studies using the HCMV BamHI 
B probe detected cell-free virus, since the low-speed centrifugation step 
of the protocol would have removed any virus associated with intact host 
cells. The sensitivity of the test with this probe was low for two 
possible reasons. (1) The nonspecific color background of the membrane 
was high. (2) There may have been a significant proportion of 
intracellular virus which was removed by the low-speed centrifugation. 
Color background is a technical problem and was corrected in later 
experiments by maintaining a constant flow of the streptavidin solution 
over the nitrocellulose membranes. The low-speed centrifugation step was 
eliminated to preserve intact cells. This meant, however, that mammalian 
cellular DNA could be present in the dot blot preparations. 
During the time that the B fragment probe was being tested, there 
was a report (135) that DNA sequences within this fragment could hybridize 
weakly with cellular DNA sequences. In other studies (18,151) two probes 
from different regions of the genome were used. In order to avoid any 
possibility of cellular DNA hybridization and to investigate the 
possibility that a combination of two probes would raise the sensitivity 
of the procedure, both BamHI D and H fragments were chosen for further 
development as probes (Figure 2). With these new probes the sensitivity 
of the test procedure increased from 52 to 81%, but the specificity 
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declined from 87. 5 to 68. 8%. The decreased specificity could be the 
result of nonspecific binding of the biotinylated probe to substances in 
the urine samples. Microscopic analysis of materials pelleted by low-
speed centrifugation showed that some urine specimens contained a 
significant number of cells, crystals, or bacteria. 
There was unexpected cross-reactivity between the HCMV D fragment 
and HSV DNA controls, which will be discussed below. For this reason the 
H fragment was tested as a single probe. The sensitivity and specificity 
results were similar to those of the combined D and H probes, but it was 
noted that the positive specimens produced only a plus/minus color 
reaction. This suggests that a single probe might prove to be less 
sensitive than the combined probes. One reason for the decreased 
sensitivity would be that there is only one region of each genome which 
can hybridize with the probe, therefore the total probe signal per genome 
would be reduced. In addition there is the possibility of variation in 
DNA sequence among clinical strains of HCMV, which might decrease the 
homology between the probe and the corresponding region of the clinical 
strain to be detected. 
Homology between HSV-1 and HCMV. The cross-reactivity between the 
HCMV BamHI D fragment and the HSV controls was investigated further. The 
HSV EcoRI M fragment specifically hybridized to this fragment. The total 
genomic homology between HSV-1 and HCMV was originally reported to be only 
5% (79). HSV-1 and Epstein-Barr virus show homology which is confined to 
specific sequences coding for proteins having related functions 
(29,60,121). Similar limited homology has now been shown to exist between 
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HSV-1 and HCMV (89,97). 
The HSV-1 M fragment codes for part of the viral DNA polymerase 
(21,59). Cross hybridization with the HCMV BamHI D fragment was observed 
within a region containing approximately 2.8 kb of the coding sequences 
of the HSV DNA polymerase (Figure 7). It has been confirmed by others 
that the specific hybridization between HCMV and HSV-1 observed in this 
study represents homology of that portion of the two polymerases which is 
highly conserved functionally among herpesviruses (58,89). 
Similar hybridization experiments were also performed to determine 
if there is homology between the HSV-1 TK and any portion of the HCMV 
genome. No separate viral TK activity has been reported to be associated 
with HCMV infection (49,177), and there have been no reports of 
experiments performed to determine possible homology between the HSV-1 TK 
gene and HCMV DNA. The fact that ACV is not phosphorylated in HCMV-
infected cells has been interpreted as further evidence that HCMV does not 
encode a TK (5). HCMV is sensitive to GCV, however, and GCV is 
phosphorylated by the HSV-1 TK. 
When the first dot-blot which was made from the HCMV BamHI library 
was probed with the HSV-1 TK sequences, there were two samples which 
hybridized more strongly with the probe (Figure 8). Attempts to reproduce 
these results by probing restriction endonuclease digests of the BamHI 
library (Figure 9) or repeat dot-blots (Figure 10) were unsuccessful. The 
two recombinants which hybridized with the HSV-1 TK region on the original 
dot-blots contained the BamHI G and J fragments. These fragments contain 
sequences from the short repeat, which has a high G+C content (129). The 
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high G+C content could cause non-specific probe hybridization, which might 
explain why the original results were not reproducible. It should also 
be noted that the 67 BamHI recombinant clones tested for HSV-1 TK homology 
may not constitute a complete HCMV library, since not all HCMV fragment 
inserts have been identified. The conclusion from these experiments and 
those of others (49,177) is, that there is not a gene encoded by HCMV, 
which is homologous at the DNA level to the HSV-1 TK. 
GCV-resistant mutants. The fact remains, however, that GCV is an 
effective therapeutic agent for treatment of HCMV infections and GCV 
requires intracellular phosphorylation for its antiviral activity. 
Resistance to GCV theoretically could be caused by mutations in two 
different genes of HCMV, the polymerase or the "GCV kinase". Biron and 
co-workers(4) demonstrated that a GCV-resistant mutant of HCMV AD169 was 
deficient in kinase activity. The three GCV-resistant mutants D6/3/l, 
Dl/3/4 and Dl0/3/2, which were isolated during this project, were 
similarly characterized to determine what function was altered. 
Multiple restriction digests of all three mutants were probed with 
the wild-type EcoRI M fragment, which encodes the polymerase gene (Figure 
12). The purpose of this experiment was to determine if a restriction 
site might fortuitously have been gained or lost in the polymerase gene 
at the site of the mutation. No differences in the hybridization patterns 
could be detected. 
In BglII digests of the mutant DNAs, however, there was an extra 
band which was present in less than one molar concentration. Quarter or 
half molar concentrations are typical of terminal and junction fragments 
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of HCMV (90). For this reason the Bglll digests were probed with a 
plasmid containing the BamHI J fragment of AD169. There was hybridization 
with the extra Bglll fragment as well as two other faint fragments (Figure 
13 lower gel). These other fragments may represent terminal variability, 
which has been described for this region (172). On further investigation, 
however, it was demonstrated that although the extra fragment was absent 
in digests of AD169 DNA extracted from infected cells, it was present in 
extracellular virion DNA of AD169 (Figure 13). HCMV DNA is replicated 
intracellularly as concatamers, therefore, the new terminal fragments may 
be generated when the DNA is packaged into virions. 
Restriction enzyme analysis did not yield any evidence of altered 
restriction sites either in the region of the HSV polymerase gene homology 
or in digests of the total genome. This does not, however, rule out a 
mutation in the polymerase gene, since there are many sites where a base 
change would not affect a restriction enzyme recognition sequence. 
Similarly changes in any other region of the genome would not necessarily 
produce detectable restriction polymorphisms, especially since only five 
restriction endonucleases were tested. Another approach to determining 
whether the GCV resistance of the mutants was a result of changes in 
polymerase or kinase function was to develop a drug-resistance profile for 
each mutant. HSV-1 drug-resistant mutants were found to cluster in two 
genes, the TK and the polymerase depending on the target of the individual 
drug. There was often cross-resistance among drugs affecting the same 
gene. For example PAA-resistant mutants were also resistant to PFA and 
AraA (20,21,22). Cross-resistance of the GCV-resistant HCMV mutants was 
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tested first by plaque dilution to determine percent survival (Table 3). 
Relatively high concentrations of each antiviral agent were chosen. The 
mutants were similar to the wild-type in their sensitivity to PAA and Aph. 
Both mutants and wild-type were relatively resistant to ACV. High-level 
GCV-resistance of the mutants was confirmed. The mutants, however, 
appeared to be slightly hypersensitive to AraA. This was somewhat 
surprising, since AraA is thought to be phosphorylated by cellular kinases 
(93). 
There are two problems with this method of quantitation. First of 
all only one concentration of drug is tested. It is conceivable, that 
lower concentrations might indicate more subtle differences in sensitivity 
or resistance between mutants and wild-type. The second problem is that 
the wild-type does not form plaques in the presence of GCV. At higher 
dilutions of the stock (above 1 x 10-3 , MOI=0.01) only enlarged single 
cells appear. These cells probably represent abortive infection, 
therefore, the amount of infectious virus produced, if any, is much lower 
than that of plaques produced in the absence of drug. The determination 
of the titer in the presence of GCV, which is measured by the highest 
dilution with only single cells, is, therefore, overestimated. 
Plaque reduction assays for quantitation of drug resistance are 
performed at a single dilution of virus. This dilution is usually 
selected such that 30-50 pfu are inoculated onto a monolayer in a 24-well 
plate. Inoculation of this amount of virus represents a relatively low 
MOI. A range of drug concentrations can, therefore, be tested for 
inhibition of plaque formation at a single MOI. This avoids one of the 
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problems with the plaque dilution method. The results of the plaque 
reduction assays confirmed the pattern of sensitivity of mutants and wild-
type determined by plaque dilution. No differences were detected among 
the mutants, and the resistance to GCV and hypersensitivity to AraA 
relative to the wild-type were reproducible. Mutant D6/3/l was further 
tested for susceptibility to AraT, FIAC and FIAU by plaque reduction 
assay. This mutant was found to be slightly hypersensitive to all three 
drugs. This is somewhat unexpected, because although AraA is probably 
phosphorylated by the cellular TK (93), AraT, FIAC and FIAU at least in 
HSV-infected cells are phosphorylated by the viral TK. 
The plaque reduction assays still have a problem similar to one 
associated with plaque dilution, namely the fact that the wild-type virus 
does not form plaques in the presence of GCV. In order to better 
quantitate the sensitivity of the wild-type virus to this agent an ELISA 
was developed. 
The ELISA detects a late HCMV antigen which requires viral DNA 
replication for its production (142). Since GCV inhibits DNA replication, 
synthesis of this antigen is especially sensitive to the effects of the 
drug. The measurement of the reduction in optical density with increasing 
concentrations of GCV is proportional to the amount of virus produced in 
each infected monolayer. This is a much better method for determining 
actual virus replication beyond abortive infection. The results of the 
ELISA confirmed the level of sensitivity of the wild-type to GCV 
previously determined by plaque dilution and plaque reduction. The high-
level resistance to GCV and slight hypersensitivity to AraA of D6/3/l were 
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also confirmed. 
There was no evidence for cross-resistance of the mutants to any of 
the drugs dependent only on polymerase activity (PAA, PFA, or Aph), but 
there still could be a mutation in the polymerase gene which did not 
affect the interaction of the enzyme with these three antiviral agents. 
In order to determine whether these mutants were phenotypically 
similar to the one described by Biron et al. (4), HPLC analysis of GCV 
anabolism within cells infected with either mutants or wild-type AD169 was 
performed. A reversed phase system was developed to distinguish GCV from 
its phosphorylated derivatives. This was different from the ion exchange 
HPLC method of Biron and co-workers (4), but the results were highly 
reproducible. All three mutants were remarkably deficient in the ability 
to phosphorylate GCV. The lack of activation of GCV within mutant-
infected cells could account for the increased resistance, but there could 
be another mutation contributing to the high-level resistance, which is 
phenotypically masked by the lack of kinase activity. 
GCV anabolism was also studied in co-infected cells. It might be 
expected that the wild-type enzyme would be dominant over the mutant, 
therefore, in co-infected cells the wild-type enzyme would be functional 
and GCV would be phosphorylated. The amount of phosphorylation of GCV in 
co-infected cells was approximately 10% of that of wild-type- infected 
cells at the same MOI. These results suggest that the mutant enzyme 
competes for the GCV substrate, or that the enzyme is a multimer. In the 
latter case mutant subunits mixed with wild- type could cause loss of 
function for the complete multimer. The mechanism of the interaction of 
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wild-type and mutant enzyme activities, however, cannot be determined from 
these experiments. 
An experiment which would be helpful in studying enzyme activity in 
co-infected cells, would be to vary the relative amounts of each virus for 
co-infection at the same total MOI. Such an experiment was attempted, but 
the only radiolabeled-GCV which was available was the 14C-GCV received from 
Burroughs-Wellcome. The specific activity of this labeled drug was 500 
mCi/mmol) while the specific activity of the 3H-GCV from Syntex was three 
times higher. The number of counts of the GCV taken up by the infected 
cells from the medium was not high enough to produce significantly 
increased peaks of phosphorylated derivatives from even wild-type-infected 
cells. One other problem with this label is that the 14c is in the guanine 
portion of the molecule (Figure 24A). The bond between guanine and the 
acyclic ring is somewhat labile, therefore when it is broken, labeled 
guanine remains, which can be phosphorylated by cellular kinases. These 
kinases are present in both mutant and wild-type-infected cells, and the 
reversed phase HPLC system cannot distinguish the phosphorylation products 
of GCV and guanine. There were similar peaks of less than 100 cpm in 
control and co-infected cells when the co-infection experiment was 
performed with 14C-GCV. From Figure 24B it is apparent that the lability 
of the bond between guanine and the acyclic ring is not a problem with the 
3H-GCV, because the label is in the acyclic ring. If the bond is broken 
the remaining guanine is not labeled. The labeled acyclic ring apparently 
does not co-migrate with any GCV anabolic products, because mutant and 
wild-type HPLC profiles are dramatically different. Unfortunately the 
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Figure 24. The structure of GCV from different sources with the position 
of the label indicated (asterisk). (A) 14C-GCV (Burroughs-Wellcome); 
label on CS. (B) 3H-GCV (Syntex); label on two hydrogens of acyclic 
ring. 
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only source of radiolabeled GCV is as a gift of the pharmaceutical 
companies which developed the drug, and the higher-specific activity 
tritiated compound is no longer available. 
Strategies for mapping the GCV kinase activity. The HPLC analysis 
of the mutants, however, did at least show that a kinase activity, whether 
virally encoded or virally modified, was greatly reduced. Three different 
approaches were taken to try to map the mutation: 1) in vitro translation 
and expression of kinase activity; 2) transfer of resistance from a mutant 
cosmid library to wild-type AD169; 3) 2-dimensional gel electrophoresis 
analysis of mutant and wild-type infected cell proteins. 
The experimental design for the in vitro translation approach to 
mapping the kinase function was based on the HSV-1 TK experiments 
performed by Preston (124) in which in vitro translated infected cell RNA 
produced an active TK product. In addition some experiments were based 
on methods used by Biron and co-workers (5) to try to express HCMV "GCV 
kinase" activity from cytosolic extracts of wild-type infected cells. 
If wild-type-infected cell mRNA could be translated and expressed 
in vitro, individual cosmid clones of the HCMV genome could be used to 
arrest the translation and expression of the enzyme activity. In this 
manner the translation product could be mapped to a specific cosmid. More 
specific mapping within the cosmid region could be achieved by the same 
type of experiment using subclones of the cosmid to arrest translation. 
The optimal conditions for the activity of the HCMV enzyme are 
entirely unknown, therefore, in order to try to develop an in vitro 
expression system similar to that of the HSV-1 TK, two different sets of 
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experimental conditions were used (Figure 21). For the first set of 
experiments the pH was 7.5 and the period of time allowed for expression 
was 5 hours. The pH was later changed to 6.1 and the expression time was 
either 5 hours or 11 hours. There were never any measurable peaks of 
phosphorylated GCV anabolic products after HPLC analysis of the expression 
reactions. The most likely explanations for the negative results are 1) 
the optimal reaction conditions for the kinase activity differ 
significantly from those of the HSV-1 TK, and therefore, were not met by 
the in vitro expression system; 2) the mRNA which was isolated at 72 h 
post-infection did not represent the peak of temporal transcription of 
kinase message, therefore there was insufficient message present for 
translation of the kinase product; 3) the specific activity of the labeled 
GCV substrate was not high enough to detect the phosphorylated products. 
Any combination of these explanations could also be responsible for the 
negative findings. In support of the last possibility, it was shown that 
the expression of the HSV-1 TK required labeled substrate of very high 
specific activity (124). The highest specific activity of labeled GCV 
that was available was approximately 30-fold lower than that of the HSV-
1 TK substrate. 
Another approach to mapping the kinase function was transfer of the 
resistance from mutant to wild-type virus by specific cosmid-cloned 
regions of the mutant genome. A cosmid library of the mutant D6/3/l was 
made. The wild-type genome was represented by either purified 
extracellular virion DNA or infectious virus. The large size of the HCMV 
DNA genome makes it difficult to transfect intact. An additional problem 
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with transfection of the DNA is that HFF take up exogenous DNA much less 
readily than do many cell lines, and unfortunately there is no cell line 
which is permissive for HCMV replication. Three different methods of 
transfecting HFF with a marker plasmid (cosmid pWE15 which encodes 
neomycin resistance) were tested: 1) calcium phosphate precipitation; 2) 
electroporation; and 3) liposome-mediated transfer with Lipofectin (BRL). 
Transfection was measured by resistance of cells to the neomycin analogue 
G418. The only method which was successful was the third method. 
In order to try to transfer resistance from mutant to wild-type 
virus different combinations of transfection order and form of the wild-
type genome were used. In some experiments both mutant cosmid and wild-
type naked DNA were co-transfected. In other experiments the wild-type 
genome was in the form of infectious virus. HFF were either infected 
first and then transfected with individual mutant cosmids (46) or the 
order of transfection and infection was reversed (157). No recombinant 
virus was isolated from any of these experiments. The technical 
difficulty of transfection of DNA into fibroblasts may have been the major 
reason for the lack of detectable recombination. It is also possible that 
the high-level resistance of the mutant to GCV is the result of more than 
one mutation. If this is the case, marker transfer of the GCV resistance 
with a single cosmid may not be possible. 
The third approach which was taken to map the kinase activity was 
analysis of viral proteins by 2-dimensional gel electrophoresis. The 
initial strategy was to compare in vitro translation products from mRNA 
isolated from mutant D6/3/l and wild-type AD169. If differences in 
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protein products could be detected, it might be possible to arrest 
translation of particular proteins with cosmid DNA. The disappearance of 
specific proteins from the 2-dimensional gels could serve to map those 
proteins to a 30 to 40 kb region of the genome. 
No reproducible differences in in vitro translated protein products 
of the mutant and wild-type were observed. It is possible that the mRNA 
isolated at 72 h post-infection, which was used for the translation 
reaction, did not contain sufficient message to produce a detectable 
protein. The reason that the mRNA was isolated at 72 h post-infection was 
that the HPLC analysis of GCV anabolism indicated that the enzyme activity 
was present between 72 and 96 h post-infection. It could be that the 
protein is stable, but the message is not, therefore mRNA isolated at 24-
48 h post-infection might represent the peak of kinase mRNA production. 
Proteins extracted from cells infected with virus were also analyzed 
by 2-dimensional gel electrophoresis. A reproducible protein difference 
between the two extracts was found by this analysis. A protein is present 
in wild-type-infected cells and missing in mutant D6/3/l-infected cells 
(Figure 23). It is also missing in Dl/3/4-infected cells and uninfected 
cell controls (data not shown). Interestingly the approximate molecular 
weight of the protein appears to be 43,000, which is very close in size 
to that of the monomers of HSV-1 TK (136). It is possible that the 
protein may be an induced or modified cellular protein, and that 
similarity to the size of the HSV-1 TK is purely coincidental. The fact 
that the protein is not present in either uninfected or mutant-infected 
cells, however, strongly suggests that it is associated with GCV kinase 
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activity. Further evidence of the specific function of the protein will 
be required to confirm this association. 
Since the most promising experimental results were obtained with the 
2-dimensional gel analysis of infected cell proteins, a logical next step 
would be to extract the protein from the gel and to try to determine a 
partial amino acid sequence. The amino acid sequence could then be used 
to map the coding region on the HCMV genome. If the coding sequence of 
the protein is found to be part of the viral genome, there are several 
possible approaches to determine its function and its role, if any, in GCV 
anabolism. 
The wild- type gene could be used as a probe to identify the 
corresponding mutant DNA sequences. The availability of both mutant and 
wild-type genes would permit DNA sequencing, which could determine if 
there is indeed a difference in this region of the genomes of the two 
virus strains. Finding a change at the DNA level, however, still does not 
link this region with GCV kinase function. 
The gene from the mutant, however, could be used for marker transfer 
studies to see if recombinant virus resistant to GCV can be detected. 
This may not work, however, if more than one mutation is required for 
high-level GCV resistance. 
A more direct approach to determine function would be to clone the 
gene or cDNA in an expression vector. Selection of the best vector and 
cell system would require some preliminary testing. It might then be 
possible to detect kinase activity in cell lines which are much easier to 
work with than HFF. 
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HCMV is the only member of the human herpesviruses for which no TK 
gene has been found. The GCV kinase activity defined by these mutants is 
the closest HCMV viral function to that of the HSV-1 TK, which has been 
characterized to date. Since GCV is the most effective antiviral agent 
for HCMV available at the present time, it will be important to 
characterize the kinase activity which is responsible for HCMV resistance. 
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